

AN ABSTRACT OF THE THESIS OF

Gino W. Gaddini for the degree of Master of Science in Nutrition presented on August 1, 2013.

Title: Effects of 12 Months of Voluntary Alcohol Self-Administration on Intracortical Bone Remodeling in a Rhesus Macaque Model

Abstract approved:

---

Urszula T. Iwaniec

Russell T. Turner

Background: Alcohol is a nonessential nutrient widely consumed throughout the world. Chronic alcohol abuse is associated with numerous adverse skeletal effects. However, prior to this study, the effects of alcohol abuse on intracortical bone remodeling in an animal model had not been investigated. Reduced intracortical bone remodeling could impair repair of microdamage accrued during activities of daily living and lead to increased risk of bone fractures.

Methods: To fill this gap in knowledge, we investigated the effects of 12 months of voluntary self-administration of ethanol (4% v/v) on bone mass, bone microarchitecture, and intracortical bone remodeling in male rhesus monkeys approaching skeletal maturity (mean age 6.7 years).

Results: Alcohol-fed monkeys consumed a mean of 2.8 g/kg ethanol per day. No significant difference was found between alcohol and control monkeys for body weight, age, or any indices of bone mass or bone microarchitecture. However, monkeys in the alcohol group had significantly lower intracortical bone formation and bone resorption compared to the control group.

Conclusions: These results suggest that 12-months of self-administration of alcohol results in significantly reduced intracortical bone remodeling without affecting bone mass or bone microarchitecture; thus, evidence from this study indicates that alcohol abuse can reduce bone quality without affecting bone quantity.

Key Words: Alcohol abuse, rhesus macaque model, histomorphometry, cortical bone remodeling.

© Copyright by Gino W. Gaddini  
August 1, 2013  
All Rights Reserved

Effects of 12 Months of Voluntary Alcohol Self-Administration on Intracortical Bone  
Remodeling in a Rhesus Macaque Model

by  
Gino W. Gaddini

A THESIS

submitted to

Oregon State University

in partial fulfillment of  
the requirements for the  
degree of

Master of Science

Presented August 1, 2013  
Commencement June 2014

Master of Science thesis of Gino Gaddini presented on August 1<sup>st</sup>, 2013

APPROVED:

---

Co-Major Professor, representing Nutrition

---

Co-Major Professor, representing Nutrition

---

Director of the School of Biological and Population Health Sciences

---

Dean of the Graduate School

I understand that my thesis will become part of the permanent collection of Oregon State University libraries. My signature below authorizes release of my thesis to any reader upon request.

---

Gino W. Gaddini, Author

## ACKNOWLEDGEMENTS

First, I would like to express my deepest gratitude and appreciation to Dr. Urszula Iwaniec and Dr. Russell Turner. Without the opportunity, mentorship, and support that you both have given me this thesis would never have been possible. I could not have asked for a better duo of advisors for my Master's Degree, and I am honored to have had the chance to work in such a prestigious laboratory as the Oregon State University Skeletal Biology Lab.

Next, I would like to thank the members of my committee. Dr. Gianni Maddalozzo, Dr. Bo Zhang, and Dr. Joy Waite-Cusic. I am honored to be affiliated with each of you, and I will strive to ensure that my future success reciprocates this honor back to you.

I would also like to thank my collaborators at the Oregon National Primate Research Center, especially Dr. Kathy Grant, Dr. Kevin Nusser, Dr. Steven Gonzales, and Cara Stull. The tissue samples, data, and support that you provided were integral in the completion of this research.

Next, I would like to acknowledge my lab mates, especially Bailey Lindenmaier, Kenneth Philbrick, Jonny Wymore, Dawn Olson, Jody Gordon, Lindsay Wagner, and Jessica Keune for creating a fun, yet productive environment in the lab.

Also, I would like to thank all of my friends and family, especially my brothers Mario and Vittorio Gaddini. Friends and family mean the world to me. Without you all, none of this research would matter.

Additionally, I want to extend my appreciation to Mele LeLievre for your love, support, and patience, as well as all the late nights you spent helping me at the lab.

Finally, although words cannot express my appreciation, I would like give my sincerest thanks to my parents, Frank and Frances Gaddini. Their love and support

has helped me to succeed in all aspects of my life, and I would not be who I am without them. Thanks Mom and Dad!

## TABLE OF CONTENTS

|   | <u>Page</u> |
|---|-------------|
| 1 Introduction.....   | 1           |
| 2 Literature Review.....  | 4           |
| 2.1 Osteoporosis.....   | 4           |
| 2.2 Bone Remodeling.....  | 4           |
| 2.3 Background on Alcohol Consumption in Humans.....                          | 5           |
| 2.4 Effects of Alcohol on Skeletal Health in Humans.....                      | 8           |
| 2.4.1 Chronic, Heavy Alcohol Consumption.....                                 | 8           |
| 2.4.2 Moderate Alcohol Consumption.....                                       | 9           |
| 2.4.3 Limitations of Human Studies.....                                       | 10          |
| 2.5 Effects of Alcohol on Skeletal Health in Rodents.....                     | 11          |
| 2.5.1 Comparison of Bone Physiology Between<br>Rodents and Humans .....       | 12          |
| 2.5.2 Methods for Delivery of Alcohol to Model<br>Chronic Alcohol Abuse ..... | 13          |
| 2.5.3 Effects of Alcohol on Bone in Rodents.....                              | 14          |
| 2.5.4 Methods for Delivery of Alcohol to Model<br>Binge Drinking.....         | 15          |
| 2.5.5 Limitations of Rodent Models.....                                       | 15          |
| 2.6 Possible Mechanisms for the Skeletal Effects of Alcohol..                 | 16          |
| 2.7 Purpose and Hypothesis.....   | 20          |
| 3 Materials and Methods.....  | 22          |
| 3.1 Animals.....  | 22          |
| 3.2 Experimental Design.....  | 22          |
| 3.3 Dual-Energy X-Ray Absorptiometry.....                                     | 23          |

## TABLE OF CONTENTS (Continued)

|  | <u>Page</u> |
|--|-------------|
| 3.4 Micro Computed Tomography.....                   | 23          |
| 3.5 Quantitative Cortical Bone Histomorphometry..... | 24          |
| 3.6 Serum Measures of Bone Resorption.....           | 25          |
| 3.7 Blood Alcohol Concentrations.....                | 25          |
| 3.8 Statistical Measures.....                        | 26          |
| 4 Results.....                                       | 29          |
| 5 Discussion.....                                    | 39          |
| 6 Conclusion.....                                    | 43          |
| Bibliography.....                                    | 44          |



## LIST OF FIGURES

| <u>Figure</u>  | <u>Page</u> |
|--|-------------|
| Figure 3.1 Volumes of interest in the femur, tibia, and lumbar vertebra.....   | 27          |
| Figure 3.2 Examples of incomplete (open) and complete (closed) osteon.....   | 28          |
| Figure 4.1 Representative histological sections of the tibial diaphysis of control (left) and alcohol (right) animals.....   | 31          |
| Figure 4.2 (A) Number of labeled osteons per square millimeter of bone in control and alcohol monkeys. (B) Mean number of incomplete osteons per square millimeter of bone in control and alcohol monkeys..... | 32          |
| Figure 4.3 Mineral apposition rate in control and alcohol monkeys.....   | 33          |
| Figure 4.4 Serum CTX levels in alcohol and control monkeys at necropsy.....  | 34          |

## LIST OF TABLES

| <u>Table</u>   | <u>Page</u> |
|--|-------------|
| 2.1 Summary of Animal Studies Investigating the Skeletal Effects of Alcohol..... | 21          |
| 4.1 Study Population.....  | 35          |
| 4.2 Effects of Alcohol on Bone in the Lumbar Vertebra.....                       | 36          |
| 4.3 Effects of Alcohol on Bone in the Femur.....                                 | 37          |
| 4.4 Effects of Alcohol on Bone in the Tibia.....                                 | 38          |

## 1- Introduction

Osteoporosis (from Greek, “porous bone”) is a disease characterized by reduced bone mass and altered microarchitecture, which results in diminished bone strength and increased fracture risk. Osteoporosis is highly prevalent, afflicting approximately 1 in 6 Americans (44 million people) [1, 2]. In the year 2000, over 9 million osteoporotic fractures were reported worldwide [3]; moreover, 54% of women in the U.S. over 50 years old will suffer an osteoporotic bone fracture during their lifetime [4]. Osteoporotic bone fracture can result in significant reductions in quality of life (debilitating pain, functional impairment, depression, and disability), as well as significant mortality [3, 5]. Roughly 24% of individuals over 50 who suffer a hip fracture will die within one year of the fracture [4]. Osteoporosis places a significant burden on society, with estimated direct medical costs of \$20 billion in 2005, which are expected to rise to \$25 billion by 2025 [5], as well as significant additional indirect costs related to poor health and need for social support. With an aging population, these numbers are expected to grow.

Throughout life, bone undergoes “ceaseless activity” [6] and is constantly being broken down and reformed in a coupled process known as bone remodeling (reviewed in Robling et al (2006) [7]). Imbalance between the relative and absolute rates of bone formation and bone resorption can affect bone quantity and bone quality, both of which are important for the structural integrity of bone. There are many factors that collectively contribute to modulation of bone remodeling and thus the risk of developing osteoporosis and risk of bone fracture, including genetics [8, 9], autoimmune disorders [10-13], endocrine disorders [14], chronic diseases (such as hepatic and renal disease [15-17]), and gastrointestinal disorders [18], as well as modifiable lifestyle factors such as diet [19], sunlight exposure [20], corticosteroid medication use [21], physical activity [22-24] and tobacco smoking [25-27]. Alcohol consumption is another important modifiable lifestyle factor that can influence skeletal health.

Alcohol consumption is highly prevalent throughout the world. In the U.S., over half of adults (roughly 131 million people) drink alcoholic beverages on one or more occasions per month [28], and around 3.8% of Americans are classified as alcohol-dependent [29]. Alcohol consumption and general health can be described as exhibiting a J-shaped curve; that is, compared to abstinence, moderate alcohol

consumption is associated with various health benefits, including improved blood lipid profiles [30-33] and improved insulin sensitivity [34-36], as well as reduced risk of cardiovascular disease [37-40], type II diabetes mellitus [41-43], Alzheimer's disease and other forms of cognitive decline [44-46], and reduced all-cause mortality [47, 48]. Conversely, chronic, heavy alcohol consumption is related to numerous negative health consequences, including deleterious effects on the cardiovascular [49], gastrointestinal [50], immune [51], nervous [52], and reproductive systems [53], as well as increased risk of certain cancers [54, 55] and a wide array of psychiatric disorders [56].

Alcohol consumption and human skeletal health also exhibit a J-shaped curve. Compared to alcohol abstinence, moderate alcohol consumption is reported to result in higher BMD [60-70] and lower fracture risk in certain populations (especially elderly men and postmenopausal women). However, other studies report no beneficial or detrimental effects of moderate alcohol on bone mineral density (BMD) or fracture risk [57-59]. In contrast, chronic heavy alcohol consumption is associated with lower BMD [57, 71-78] and increased fracture risk in both men and women [73, 78-80].

While BMD is a predictor of bone fracture risk in the general population [81-84], the increased fracture risk associated with alcohol abuse in humans is greater than what is explained by decreased BMD alone [85], indicating that alcohol abuse negatively affects bone quality. Histological analyses of cancellous bone (spongy bone) in the iliac crest of human alcoholics have demonstrated that the percentage of cancellous bone covered by osteoblasts (bone forming cells) or incorporating tetracycline label (reflecting bone mineralization) are significantly decreased in alcoholics [76, 86-89], indicating that heavy alcohol consumption reduces cancellous bone formation. These findings are corroborated by reports of reduced serum biomarkers of bone formation in alcoholics compared to controls [58, 71-74, 76, 90-93]. The effects of heavy alcohol consumption on histological and biochemical markers of bone resorption in humans are less clear however, with some groups reporting lower resorption [86], others reporting higher resorption [87, 90, 92, 94], and some reporting no effect [76]. Findings in humans are replicated in rat models for alcohol abuse, which have shown that chronic, heavy alcohol consumption is associated with lower BMD

[95-98], as well as lower histological indices of cancellous bone remodeling at multiple skeletal sites [95, 96, 99]. Additionally, findings in animals have suggested that alcohol abuse is associated with altered microarchitecture in cancellous and cortical bone [95-97, 101] and lower compressive and tensile breaking strength [99, 101-104]. Thus, there is good evidence substantiating that alcohol does indeed disrupt global bone remodeling, and there is strong evidence that alcohol reduces cancellous bone remodeling; however, the effects of alcohol abuse on intracortical bone remodeling are not known. Since cortical bone comprises nearly 80% of skeletal mass [105] and is crucial for structural support, alcohol-induced alterations in intracortical bone remodeling may play a critical role in fracture risk.

Studies in humans are complicated by numerous factors, including alcoholism-associated comorbidities with alcohol-independent skeletal effects (such as malnutrition, tobacco smoking, illicit drug use, and chronic disease), the validity and reliability of alcohol consumption assessment, and the invasiveness of analysis of intracortical bone remodeling. Additionally, prospective alcohol intervention studies are difficult to conduct in humans for ethical reasons. Thus, it is challenging to accurately assess the effects of alcohol, especially alcohol abuse, on bone in humans. Rodent models allow circumvention of many of these limitations; however, rodents do not exhibit intracortical (Haversian or osteonal) bone remodeling (the primary process through which cortical bone is remodeled in humans); thus, the effects of alcohol on intracortical bone remodeling cannot be examined in rodents.

To understand the effect of alcohol on intracortical bone remodeling, and how this may relate to fracture risk in alcohol consumers, we used a rhesus macaques (*Macaca mulatta*), non-human primate model for chronic alcohol abuse. Unlike rodents, rhesus monkeys exhibit intracortical remodeling that closely resembles bone remodeling in humans [106]. Thus, this is a very relevant model for the skeletal effects of alcohol abuse. The primary purpose of this investigation was to evaluate the effects of alcohol abuse on cortical bone mass, density, and intracortical remodeling in young adult rhesus monkeys.

## **2- Literature Review**

### **2.1 Osteoporosis**

Osteoporosis is a major public health concern, which can lead to compromised bone strength and increased fracture risk. Nearly 1 in 6 Americans (44 million people) are affected by osteoporosis [1, 2], and with an aging population this number will only increase. Osteoporotic bone fracture can lead to significant reductions in quality of life (such as debilitating pain, functional impairment, depression, and disability [5]), as well as significantly increased risk of mortality [3]. In 2000, it was estimated that there were 9 million osteoporotic fractures worldwide [3]. In the U.S., about 54% of women over 50 will have an osteoporotic bone fracture; further, 24% of individuals over 50 who suffer a hip fracture will die within one year of the fracture [4]. Osteoporosis places a significant financial burden on society, with estimated direct medical costs of \$20 billion in 2005, which are expected to rise to \$25 billion by 2025 [5].

### **2.2 Bone Remodeling**

Throughout life, bone undergoes “ceaseless activity” [6] and is constantly being broken down and reformed in a coupled process known as bone remodeling. A comprehensive review of bone remodeling can be found in Robling et al (2006) [7]. Briefly, at the initiation of bone remodeling, bone-resorbing cells (osteoclasts) are recruited to previously quiescent bone surfaces, where they degrade bone via secretion of protons and pH-sensitive enzymes. Following resorption, growth factors released from degraded bone facilitate the recruitment and activation of bone forming cells (osteoblasts) to the resorption site. Osteoblasts secrete a collagenous matrix and then facilitate the mineralization of this matrix to form bone. The end result of each remodeling cycle is the production of a new Basic Multicellular Unit (BMU), which is the functional unit of bone remodeling.

Proper regulation of bone remodeling is integral for maintaining the structural integrity of bone, as well as maintaining mineral homeostasis. An increased rate of bone resorption relative to formation will eventually result in a loss of bone mass, which is associated with increased risk of traumatic and non-traumatic bone fractures [81-84]. Moreover, bone quality can be negatively impacted when bone remodeling becomes abnormally low or high. Continuous bone remodeling is necessary for repair of

microfractures generated by activities of daily living. Impaired bone remodeling can lead to an accumulation of microfractures. An accumulation of microfractures reduces mechanical strength and eventually increases the probability of suffering a more severe bone fracture [107].

There are two types of bone, (1) cortical (compact) bone and (2) cancellous (trabecular or spongy) bone. Cortical bone turns over at a rate of 2-3% per year, while cancellous bone turns over slightly faster [7]. Due to the slow rate of turnover in bone tissue (relative to other tissues such as dermal and intestinal tissue), pathological (or beneficial) alterations in the bone remodeling process may take months to years to manifest changes in mass, density or architecture.

There are many factors that collectively contribute to skeletal health, including genetics [8, 9], autoimmune disorders [10-13], endocrine disorders [14], chronic diseases (such as hepatic and renal disease [15, 16]), and gastrointestinal disorders [18], as well as modifiable lifestyle factors such as diet [19], sunlight exposure [20], corticosteroid medication use [21], physical activity [22-24], tobacco smoking [25-27], and alcohol consumption.

### **2.3 Background on Alcohol Consumption in Humans**

Humans have been consuming alcohol for a long time. Evidence of intentionally fermented alcoholic beverages dates back to the Neolithic period (circa 10,000 B.C.) [108]. Historically, alcoholic beverages have been consumed for numerous reasons. Alcoholic beverages have served as a source of nutrients and as a safe thirst quencher, and have been used for their antiseptic, analgesic, and mood altering properties [108]. Today alcohol is consumed throughout the world regularly.

In the U.S., a standard alcoholic drink is defined as 14 g (or 17.7 mL) of pure ethanol. This is roughly equivalent to 12 fluid ounces of beer, 8 fluid ounces of malt liquor, 5 fluid ounces of wine, or 1.5 fluid ounces (a “shot”) of 80-proof distilled spirits (e.g. vodka, whiskey, rum, or gin) [109]. According to the U.S. *Dietary Guidelines for Americans*, it is recommended that otherwise healthy adults limit alcohol consumption to moderate levels, which are defined as 1 standard drink (14 g) per day for women and 2 standard drinks (28 g) per day for men [110]. In the U.S, purchasing alcohol is

illegal for individuals under 21 years of age, and alcohol abstinence is recommended for pregnant and breastfeeding women [110]. The definition of a standard drink and alcohol consumption recommendations vary among nations; for example, in the United Kingdom, Australia, Finland, and Japan a standard drink is defined as 8, 10, 12, and 19.75 g of pure ethanol respectively [111]. Furthermore, in the United Kingdom it is recommended that women limit alcohol consumption to 16-24 g/d and men limit alcohol consumption to 24-32 g/d. Additionally, alcohol recommendations in the United Kingdom allow for some consumption of alcohol by minors ( $\leq 1$  drink/wk for 15-17 year olds while under adult supervision) and pregnant women ( $\leq 2$  units on  $\leq 2$  d/wk after the first 3 months of pregnancy).

Alcohol consumption is highly prevalent and bridges social, economic, racial, and educational gaps. According to data from several recent national surveys, approximately two thirds of U.S. adults have consumed alcohol during the past year, and over half of adults (or around 131 million people) have reported drinking during the month prior to being surveyed [28]. Approximately 1 in 4 adult Americans reported engaging in at least one binge-drinking episode in the past month (consuming  $\geq 5$  drinks within a period of several hours). Approximately 1 in 6 adults in the U.S. reported having 4 binge-drinking episodes per month, consuming an average of 8 drinks per binge [112]. Roughly 16.9 million Americans (6.7% of the population) have engaged in heavy drinking in the past 30 days (consuming  $\geq 5$  drinks on the same occasion on  $\geq 5$  days out of the past 30 days) [112], and around 3.8% of Americans meet the criteria of alcohol dependence [29].

Demographically, in the U.S., men are more likely to drink than women (~60% of men versus ~44% of women consumed alcohol in the past month) [28, 112]. Drinking prevalence is greater with more education (36.8% of adults with less than a high school education versus 69.1% of college graduates drink). Individuals in the 21-25 year old age group were the most likely to consume alcohol (70% of people in this group), and the prevalence of alcohol use decreases with age from 65.3% in 26-29 year olds to 51.6% among 60-64 year olds and 38.2% in individuals older than 65 [112]. Several 2011 national surveys found that 25-40% of youth (aged 12-17 years old) have consumed alcohol. Although the rate of alcohol use in youths has decreased



in the past several years, the 2010 National Survey on Drug Use and Health reported that 13.6% of youths consumed alcohol in the past 30 days, 7.8% engaged in binge drinking, and 1.7% were classified as heavy drinkers [112, 113]. These surveys support the conclusion that alcohol consumption is pervasive in American society, and that alcohol abuse is a major public health concern in the United States.

Detrimental health effects of alcohol abuse have been known for a long time; documented negative physiological consequences of alcohol abuse date back to the 11th century A.D. [108]. Research has demonstrated that excessive alcohol consumption is associated with deleterious effects on the cardiovascular [49], gastrointestinal [50], immune [51], nervous [52], and reproductive systems [53], as well as increased risk of certain cancers [54, 55] and a wide array of psychiatric disorders [56]. On the other hand, compared to alcohol abstinence, moderate drinking is associated with numerous health benefits. Moderate alcohol consumption has been shown to decrease serum LDL and triglyceride concentrations, lower blood pressure, decrease collagen-induced platelet aggregation, and increase plasma HDL levels in both men and women [30-33]. Numerous reviews and meta-analyses have concluded that moderate alcohol intake is associated with significantly decreased risk of heart disease [37, 38] and stroke [39, 40]. Moderate alcohol consumption may even negate the negative effects of high saturated fat diets on cardiovascular disease risk [114]. Moderate alcohol consumption is also associated with enhanced insulin sensitivity [34-36] and reduced risk of type II diabetes [41-43]. Additionally, light-to-moderate drinking is linked to a reduced risk of Alzheimer's disease and other forms of cognitive decline [44-46], as well as reduced risk of all-cause mortality [47, 48]. However, these protective effects of moderate alcohol may not extend to all populations, such as people with liver disease, recovering alcoholics or drug users, or people with mental disorders [115]. Additionally, while there is considerable evidence for the beneficial effects of alcohol on general health in humans, this conclusion is not unanimous in the literature. Shaper et al (1988) proposed the "sick quitter" hypothesis, in which formerly moderate drinkers cease drinking alcohol due to health issues or potential prescription drug interactions, thus inflating the number of "sick" abstainers and skewing the results of epidemiological studies [116]. Overall, the relationship between alcohol use and overall human health can be described as having a U- or J-shaped curve; however,

there is insufficient evidence to make a clear public health recommendation regarding the optimal amount of alcohol consumption, and this optimal level likely among between individuals.

## **2.4 The Effects of Alcohol on Skeletal Health in Humans**

Similar to the relationship between drinking and general health, evidence in the literature suggests that chronic, heavy alcohol consumption in humans has serious negative skeletal consequences, while low-to-moderate drinking has no detrimental skeletal effects, and may even be beneficial in certain populations.

### **2.4.1 Chronic Heavy Alcohol Consumption**

The general consensus in the scientific literature is that chronic, excessive alcohol consumption is associated with poor skeletal health. BMD is commonly assessed in clinical settings using dual X-ray absorptiometry (DXA) and is often used to predict fracture risk. Epidemiological and case-control studies using DXA to assess bone in alcoholic patients have associated chronic, heavy alcohol consumption with reduced BMD at multiple weight bearing and non-weight bearing skeletal sites [57, 71-78], as well as increased risk of bone fracture in both men and women [73, 78-80].

Histomorphometric analyses of transiliac biopsies from alcoholic hospital patients have shown that chronic heavy alcohol consumption is negatively associated with histological indices of bone formation [76, 86-89]. A case-control study by Crilly et al (1988) compared transiliac biopsies from male alcoholic patients admitted to a Veterans' Administration hospital (n=16, age = mean $\pm$ SD = 65.3 $\pm$ 7.3) to transiliac biopsies from age-matched volunteers who abstained from drinking (n=9, age = 63.3 $\pm$ 6.0). They found that the percentage of bone covered in osteoblasts or incorporating tetracycline label (signifying bone formation) was significantly decreased in alcoholics, suggesting reduced bone formation [88]. Another case-control study by Schnitzler et al (2010) compared 16 male chronic alcoholic patients with pancreatitis (age = 41 $\pm$ 9 years, duration of alcohol abuse=7-26 years, mean alcohol consumption=170 g/day) to 37 healthy, age-matched male volunteers. Analysis of transiliac biopsies showed that endocortical osteoid surface, mineral apposition rate, and bone formation rate were decreased, and endocortical eroded surface was

increased in the cortical bone of alcoholics compared to controls; however, no statistical differences were found in intracortical osteoid thickness or surface, eroded surface, mineral apposition rate, or bone formation rate, suggesting that in cortical bone alcohol may reduce formation and increase resorption on endocortical surfaces but have no effect on intracortical remodeling. Additionally, this group also showed that trabecular bone volume and trabecular thickness were significantly decreased in alcoholics compared to controls [89]. However, it should be noted that the alcoholic patients in this study had multiple comorbidities that could independently affect bone metabolism, including pancreatitis and type II diabetes.

In general, histological findings of reduced bone formation are corroborated by reports of reduced serum and urinary bone formation biomarkers (e.g. osteocalcin) in alcoholic patients compared to controls [58, 71-74, 76, 90-93]. However, the effects of heavy alcohol consumption on histological and biochemical markers of bone resorption in humans are less consistent, with some groups reporting lower resorption [86], others reporting higher resorption [87, 90, 92, 94], and some reporting no effect [76]. Furthermore, in a number of studies of former heavy alcoholics (>84 g/d for >5 years), BMD and biomarkers of bone formation were compared prior to and after periods of abstinence (thus, subjects served as their own controls). Results showed that BMD was higher after abstinence for 6 months [71] to 2 years [117], and that abstaining for periods of 7 days to 2 years resulted in significant increases in serum bone formation markers [58, 92, 94].

#### **2.4.2 Moderate Alcohol Consumption**

In contrast to alcohol abuse, numerous studies have associated light-to-moderate drinking with beneficial skeletal effects compared to abstinence. However, this association may not be true for all populations. Epidemiological studies have shown that in post-menopausal women and elderly men, moderate alcohol consumption is associated higher bone mass and with smaller decreases in BMD and BMC at multiple weight-bearing and non-weight-bearing skeletal sites compared to non-drinkers [60-69]. In younger and middle-aged men, the effects of moderate alcohol consumption on BMD are less clear, with some studies showing a positive relationship [59, 62, 69, 70] but others showing no effect [57]. A lack of a relationship between

moderate alcohol intake and bone mass has also been reported in premenopausal women [58, 59]. This discrepancy could potentially be due to an insufficient duration of alcohol consumption in younger individuals to manifest alterations in BMD. Or, alcohol may be counteracting the skeletal effects of disrupted endocrine function resulting from advancing age. For instance, estrogen deficiency in postmenopausal women results in increased bone remodeling such that resorption outpaces formation [118]. Moderate alcohol consumption is associated with decreased serum and urinary markers of bone resorption and formation in post-menopausal women [67]. A prospective study by Marrone et al (2012) found that in moderate drinking ( $19 \pm 1$  g/d) postmenopausal women (age  $56.3 \pm 0.5$  years), serum osteocalcin and carboxy-terminal collagen crosslinks (CTX) levels were increased after two weeks of alcohol abstention, suggesting that moderate alcohol consumption can decrease the rate of bone turnover in postmenopausal women [65]. Thus, moderate alcohol intake may be beneficial in postmenopausal women, in part, by counteracting the effects of estrogen deficiency on bone turnover rate.

#### **2.4.3 Limitations of Human Studies**

Although results of studies in humans are very valuable, there are numerous issues that affect interpretation of results. For example, many of the studies are retrospective. The validity and reliability of assessing alcohol consumption retrospectively is questionable, especially in alcoholics, who may not be able to accurately recall the quantity of alcohol they regularly consume. Additionally, alcoholism is associated with numerous factors known to have alcohol-independent skeletal effects: irregular feeding behavior and malnourishment are common in alcoholics [74, 119], many suffer from chronic diseases (e.g. liver, kidney, and pancreatic disease), and many engage in lifestyle factors such as cigarette smoking, illegal drug use, and/or physical inactivity. Furthermore, studies in humans may not be generalizable. Most studies have been done in middle aged and elderly white men and women, and skeletally immature individuals have been under-investigated. Also, there is a lack of consensus on the exact definition of light, moderate, and heavy alcohol consumption among studies. There is a large discrepancy in the amount of alcohol consumption defined as moderate. Additionally, there is evidence that the type of alcoholic beverage (e.g. beer, wine, or spirits) may potentially differentially affect the

skeleton [61, 66, 69, 120]. Furthermore, most studies in humans have reported alcohol consumption as a volume (or mass) of alcohol consumed per day. However, factors such as the rate and concentration of alcohol consumed, the amount and composition of foods present in the gastrointestinal tract with imbibed alcohol can affect the ethanol concentrations experienced at the cellular level independent of the volume of alcohol consumed. Blood alcohol concentrations would likely be a better measure to assess the skeletal effect of alcohol compared to the volume or duration of alcohol consumption; however, there is presently limited data on blood alcohol concentrations from studies designed to evaluate skeletal endpoints. Also, prospective studies investigating the effects of chronic, heavy alcohol consumption are difficult due to the long duration needed to see significant alterations in bone microarchitecture and bone mass, as well as ethical reasons (due to the documented negative health effects of alcohol abuse). Fortunately, several animal models for the effects of alcohol on bone have been effectively used to circumvent many of the limitations of human studies [121].

## **2.5 Effects of Alcohol on Skeletal Health in Rodents**

A variety of animal models, including rodents, rabbits, dogs, and primates, have been used to model the skeletal effects of alcohol (the strengths and weaknesses of animal models for assessing skeletal health are reviewed by Iwaniec et al (2008) [121]). In the past decade, the laboratory rat has been the preferred animal for the majority of researchers. The benefits of rat models are that they have a relatively short lifespan, grow rapidly, are inexpensive, allow for strict control of diet and other variables, and have well characterized skeletons that serve as good models for a number of skeletal conditions [122]. Additionally, established protocols exist for hormonal interventions, immobilization, fracture healing, dietary manipulations, and numerous well characterized techniques are available to assess the effects of alcohol on bone, including DXA [123], peripheral quantitative computed tomography (pQCT) [124], micro computed tomography ( $\mu$ CT) [125], histomorphometry [121], and mechanical load tests.

### **2.5.1 Comparison of Bone Physiology Between Rodents and Humans**

Bone growth and remodeling between humans and rodents (especially rats) share many similarities, which allow these animals to be good models for various aspects of the effects of alcohol on skeletal health. Similar to humans, rats undergo BMU-based endocortical and cancellous bone remodeling [126, 127]. Both rats and humans exhibit slow increases in cross-sectional bone area throughout the lifetime, resulting in life-long periosteal expansion [128, 129]. Additionally, both humans and rats exhibit endochondral ossification that slows in magnitude and ultimately ceases [130]. Like in humans, bone remodeling rate in rodents is not constant throughout life; thus, the age of the animals used is important for assessing the effects of alcohol on bone turnover. Rats undergo a rapid rate of bone growth during the first 3 months of life, which peaks around 6 weeks of age and then rapidly declines with increasing age [122]. Following this rapid growth phase, endochondral ossification slows and eventually ceases [130] while periosteal bone formation continues slowly throughout life. By 7.4 months of age in males and 6.5 months in females, longitudinal bone growth ceases through epiphyseal closure mediated by bone bridging [130], and there is a marked decrease in bone turnover rate during skeletal maturation in rats [126]. A study by Baron et al (1984) showed that, despite having similar trabecular bone volume, 8-week old rats had 5 times higher bone formation rate and 5 times more osteoclasts than 12-week old rats [126]. Most studies investigating the effects of ethanol consumption in rats during the past decade have been done in rapidly growing animals (See Table 2.1).

In contrast to humans, intracortical remodeling (the process through which cortical bone is remodeled in humans) is largely absent in rodents [131, 132]. Instead, bone remodeling in rodents is limited to endocortical and cancellous bone surfaces. Thus, rodents are poor models for investigating the effects of alcohol on intracortical bone remodeling [122]. Cortical bone is critically important in the skeletal system, providing much of the mechanical strength of bone. To date, due to lack of appropriate animal models, there has been no investigation into the effects of alcohol on intracortical bone remodeling. Primates, on the other hand, undergo intracortical remodeling similar to that in humans making them a good model for studying

intracortical bone remodeling; however, due to limitations (such as financial cost) relatively few alcohol studies have been done in non-human primates.

### **2.5.2 Methods for Delivery of Alcohol to Model Chronic Alcohol Abuse**

To model chronic alcohol abuse, ethanol has been administered through several different methods, including mixing ethanol in drinking water, alcohol-containing liquid diets, and total enteric nutrition. The simplest method of alcohol delivery is through mixing ethanol in water (usually 4-5% v/v); however, animals show aversion to consuming higher concentrations of ethanol in water, which can cause decreased fluid intake and dehydration [133]. Additionally, macronutrient and micronutrient imbalance between treatment and control groups may become an issue as treatment animals receive nutrition from both chow and alcohol while control animals only receive nutrition through chow [133]. Thus, changes observed in bone may be the result of micronutrient or caloric differences and not from ethanol. To circumvent some of the limitations of administering ethanol through drinking water, the majority of animal studies in the last decade have administered alcohol through standardized liquid diets (see Table 2.1), such as the Lieber-DeCarli diet [133], which contain either ethanol or an isocaloric amount of simple carbohydrate. However, a study by Maddalozzo et al (2009) showed that when given *ad libitum* access to liquid diets containing either 35% of kcals as (1) ethanol or (2) maltose-dextrin (control), ethanol-fed animals gained significantly less weight than control animals [96]. When control animals were pair-fed to alcohol animals, body weight differences were resolved; however, pair-fed controls had significantly reduced bone volume and bone formation compared to *ad libitum* controls, suggesting that caloric restriction in rats fed ethanol-containing liquid diets may have skeletal effects independent of alcohol. In many studies using liquid diets, animals were not pair fed and the body weights of ethanol-fed animals were either not reported or were significantly lower than controls [103, 104, 134, 135]; thus, in these studies it is difficult to separate the effects of alcohol from the potential effects of malnourishment on skeletal phenotypes.

Total enteric nutrition (TEN) has also been used to administer ethanol in rats [136-138]. TEN involves implantation of a tube into the wall of the stomach; this tube is tunneled subcutaneously to the head and attached to a headpiece through which the

animal receives infusion of a liquid diet. Compared to ethanol mixed in drinking water or liquid diets, TEN allows for exquisite control of (1) caloric intake and dietary composition, (2) the volume, duration, and rate of alcohol ingestion, and (3) blood alcohol concentrations; additionally, TEN is an effective method to administer very high concentrations of ethanol. However, TEN is invasive, and it is conceivable that stress on an animal due to placement of the feeding tube may affect bone independent of alcohol, although this has not yet been thoroughly examined.

### **2.5.3 Effects of Alcohol on Bone in Rodents**

Compared to controls, in skeletally immature (6- to 12-week old) rats administered 26-35% of kcals as ethanol for 6 to 16 weeks, (1) gains in BMD are reduced in the femur, tibia, lumbar vertebra, and in the whole body [96-98, 101, 103, 104, 139], (2) cancellous bone volume/tissue volume ratio and trabecular thickness are lower, and trabecular separation is generally higher [96, 97, 103, 140] (although some studies show no significant change in trabecular separation [141]), (3) cortical medullary area, cortical porosity, and pore number are higher and cortical thickness is lower in some but not all studies [96, 97, 142, 143], and (4) compressive and tensile breaking strength is lower [99, 101-104]. In skeletally mature rats (>8 month old), studies modeling alcohol abuse have reported bone loss. Administration of 35% of kcals as ethanol for 12-16 weeks decreases the ratio of bone volume to tissue volume [100, 144], causes thinning of the trabeculae [100, 135], thinning of cortical bone [135], and compromises mechanical strength [144].

Furthermore, studies have shown that alcohol administration in rats reduces histomorphometric indices of bone formation (i.e. osteoblast perimeter and mineralizing perimeter/bone perimeter ratio) in both skeletally immature [95, 96, 99] and skeletally mature rats [100]. Turner et al (2001) showed that bone formation in skeletally mature 8-month old rats can be reduced dose-dependently by administration of as little as 3% of kcal as ethanol [100]. Furthermore, administration of alcohol (1) impairs fracture healing in rats [136, 137, 145, 146] with as little as 7.2% of kcal as ethanol [147], (2) impairs osteoinduction in demineralized allogeneic bone matrix (DABM) implants [142, 148], and (3) reduces the mechanical strength during fracture repair [149-151].



#### **2.5.4 Methods for Delivery of Alcohol to Model Binge Drinking**

Rats have also been used to model the skeletal effects of binge drinking. Many studies have attempted to model binge drinking via daily intraperitoneal (IP) injections of large doses of ethanol. Studies have shown that once daily injections of 3 g ethanol/kg body weight on 3 consecutive days per week for 4 weeks in skeletally immature (7-16 week old) rats results in significantly reduced whole body BMD and cancellous BMD in the tibia and lumbar vertebra (assessed via peripheral quantitative computed tomography) [152-155], but no change in cortical BMD in the tibia or lumbar vertebra compared to controls [154, 156]. The same alcohol administration regimen is also associated with altered bone microarchitecture [152], lower compressive strength in the lumbar vertebra [153-156], reduced serum osteocalcin (a biomarker of bone formation) [154], and suppressed expression of numerous genes involved in bone formation [153, 156, 157]. However, IP injection may have alcohol-independent effects that could preclude accurate extrapolation of results. Once daily IP injection of 1.2 g ethanol/kg body weight for 7 days in 4-month old female rats causes reduced body weight, suppressed periosteal and cancellous bone formation, and decreased expression of bone matrix proteins compared to oral gavage of the same dose of ethanol [158].

#### **2.5.5 Limitations of Rodent Models**

Modeling human drinking behavior in animals can be challenging, as many human drinkers have irregular patterns of alcohol consumption that can range from occasional, to regular, to binge or combinations of regular and binge drinking. While administration of alcohol via a liquid diet, mixed in drinking water, or IP injection allows control of pattern of alcohol administration, it does not necessarily model the voluntary patterns of human drinking. Additionally, most studies done in rodents have been done in skeletally immature, male rats given very high doses of ethanol. See Turner et al (2001) for review of studies prior to the year 2000 [122] and Table 2.1 for review of studies post 2000. These studies in rodents essentially model excessive, continuous alcohol consumption in young, growing individuals. As a result, it is unclear whether involuntary consumption of alcohol or involuntary caloric restriction may impact the skeleton. However, reduced caloric intake, which is common with alcohol abuse, has negative effects on bone [159, 160]. Furthermore, rodents are not humans. As

previously mentioned, rodents do not exhibit intracortical remodeling, which is the process through which humans remodel cortical bone; thus, rodents are poor models for human cortical remodeling. Cortical bone comprises nearly 80% of bone mass and provides much of the structural support. The effects of alcohol on cortical bone remodeling are poorly understood, yet they are of significant clinical relevance. Due to the prevalence and severity of osteoporosis and osteoporotic fractures there is a critical need to understand the effects of alcohol on cortical remodeling.

To circumvent limitations of rodent models we have used a primate model of voluntary self-administration of alcohol. By undergoing intracortical remodeling similar to humans, primates are a physiologically relevant model. Importantly, this model allows investigation of intracortical bone remodeling in response to alcohol consumption patterns similar to those of human alcoholics [161].

## **2.6 Possible Mechanisms for the Skeletal Effects of Alcohol**

The cellular and molecular mechanisms underlying the effects of alcohol on bone are not fully understood. It is likely that the actions of alcohol on bone are mediated through a combination of several mechanisms that act on numerous physiological systems. Cell culture studies have shown that high concentrations of ethanol can (1) act directly on osteoblasts to decrease their activity [162, 163], inhibit differentiation from progenitor cells [162, 164-168], induce senescence pathways [169], and stimulate expression of receptor activator of nuclear factor kappa-B ligand (RANKL, an osteoclastogenic factor) [170], (2) act directly on osteoclasts to increase their activity and differentiation [162, 171], and (3) directly induce apoptosis of osteocytes [97, 172, 173]. Several *in vitro* studies have shown that alcohol directs differentiation of mesenchymal stromal cells (which are progenitors for both the adipocyte and osteoblast lineages [174]) into adipocytes rather than osteoblasts [163, 173, 175-177], which could explain the increased marrow adiposity and decreased bone mass observed after chronic heavy alcohol consumption in rat models [96, 139]. Additionally, acetaldehyde, the main metabolite of ethanol has also been shown to decrease osteoblast activity and differentiation in culture [178, 179]. There is also *in vitro* evidence that chronic high levels of ethanol exposure may act directly on bone cells to suppress the Wnt/B-catenin signaling pathway [153, 156, 180], which plays an

important role in the regulation of genes involved in the function, apoptosis, proliferation, and differentiation of bone cells [181]. However, most of these aforementioned *in vitro* studies have exposed bone cells to ethanol concentrations that are unlikely to be achieved in living organisms; thus, drawing the conclusion that alcohol might directly affect bone cells requires additional *in vivo* support.

In addition to possible direct effects of alcohol on bone cells, there is strong evidence that alcohol may act indirectly on the skeleton through combinatorial effects on numerous physiological systems. Alcohol may affect the intake, absorption, metabolism, and excretion of micronutrients that are critical to bone health (such as calcium, magnesium, and vitamin D). Human alcoholics often have poor diet and voluntarily replace nutrient dense foods with alcohol [182]; thus, many alcoholics may suffer from deficient intakes of nutrients critical to bone health.

Chronic alcoholism is also associated with kidney and liver disease in humans [15-17] and cynomolgus monkeys [183]. Kidney and liver disease can result in deregulated absorption, metabolism, and excretion of nutrients involved in bone health. There is also evidence that alcohol disrupts the concentrations and activity of calcium regulating hormones, including vitamin D, parathyroid hormone (PTH), and calcitonin. Alcoholism in humans has been associated with decreased serum 1,25 dihydroxyvitamin D [71, 184] and serum 25-hydroxy-vitamin D [57, 89], as well as decreased serum PTH [184]. Decreases in vitamin D and PTH can indirectly lead to decreased bone mass and bone formation rate through impaired osteoblast function and differentiation, as well as impaired intestinal calcium absorption [185]. However, not all studies have reported alterations in serum vitamin D or PTH due to alcoholism [57, 71, 86, 89]. Studies in rats have shown that although abnormal vitamin D metabolism is observed in alcohol-fed rats, changes in vitamin D levels are preceded by changes in bone metabolism; thus, it is uncertain whether abnormalities in vitamin D levels are a cause or consequence (or both) of alcohol abuse.

Alcohol abuse is often associated with irregular feeding behaviors and reductions in fat mass and lean tissue mass in humans and rats [73, 96]. Fat mass and lean mass are both positively correlated with BMD [186, 187]. Reduced lean tissue

mass may decrease the mechanical stimulus in exercised-induced bone gain through reduced muscle force production and theoretically contribute to lower BMD [188]. Reduced fat mass may alter signaling of bone active hormones secreted from adipocytes; in particular leptin, an adipocyte secreted cytokine involved in food intake and body weight regulation. Leptin may act both centrally and peripherally to regulate bone mass [189]. Leptin stimulates the differentiation of human marrow stromal cells into osteoblasts and inhibits differentiation into adipocytes [190]. Alcohol consumption has been shown to decrease leptin concentrations in rats [96, 97] and humans [191].

Alcohol may also indirectly affect bone by inducing skeletal resistance to growth hormone [192]. Growth hormone stimulates differentiation of stromal cells into osteoblasts and suppresses adipocyte differentiation [193]. Both alcohol and growth hormone deficiency result in similar skeletal responses: reduced bone growth and turnover and increased marrow adiposity [193, 194]. In a study investigating hypophysectomized rats simultaneously given alcohol and growth hormone, alcohol consumption was shown to impair the effects of growth hormone on both tibial growth and cancellous bone formation [192]. Many of the actions of growth hormone on cells are mediated through insulin like growth factor-I. Heavy chronic alcohol consumption is associated with decreased insulin like growth factor-I expression in bone [195], decreased hepatic synthesis of insulin like growth factor-I binding proteins [195, 196], and decreased serum insulin like growth factor-I in both rats [96, 142, 196, 197] and humans [198]. The disruption of growth hormone/insulin like growth factor-I signaling by chronic alcohol abuse could be achieved through either (1) decreased hormone bioavailability and/or (2) end organ resistance [192], and disruption of this signaling could lead to bone loss.

Alcohol-induced effects on sex hormones have also been found to influence bone metabolism. Numerous studies have associated testosterone deficiency with low BMD in male and female humans [199-209], and studies in orchidectomized male rats have shown that androgen deficiency results in altered bone metabolism [210], reduced periosteal bone formation [211], cancellous osteopenia [212], impaired radial and longitudinal growth in long bones [211, 213], and decreased BMC/BMD with aging [214]. There are conflicting results on the effects of chronic heavy alcohol consumption

on serum testosterone levels, with some studies reporting decreases in both humans [70, 73] and rats [103] and others finding no effect of chronic heavy alcohol consumption in either humans [86, 88, 90, 215] or rodents [95, 104]. However, there is evidence that serum testosterone levels are acutely diminished following bouts of alcohol consumption in humans [216-219], macaque monkeys [220], and rats [221-223]. Rodent work shows that acute alcohol administration results in drastic reductions in serum testosterone levels, which return to normal levels after 2 hours [222]. These reductions may be dose-dependent [220, 221]. Interestingly, moderate alcohol is associated with increased plasma total and free testosterone levels [224].

Estrogens influence bone physiology throughout life [225] and play a role in limiting the activation of new bone remodeling units, as well as the maintenance of proper balance between the activity of osteoblasts and osteoclasts. Estrogen deficiency results in increased amounts of bone actively undergoing remodeling. Since actively remodeling bone has reduced mechanical strength, estrogen-deficiency-induced reduction in bone quality can increase fracture risk [118]. Estrogen deficiency results in a remodeling imbalance in which resorption outpaces formation, which can cause reduced bone mass over time [118]. Lower serum estrogen is associated with lower BMD at multiple skeletal sites in elderly men and women [59, 207], and estrogen replacement therapy delays decreases in bone mass [226], and decreases fracture risk [227]. There is evidence that moderate alcohol may modulate the effects of estrogen on bone through increased estrogen receptor alpha expression [228, 229], increased aromatization of testosterone to estrogens [230, 231], decreased clearance of estrogen [232] (via direct inhibition of estradiol catabolism by ethanol [233]), or a combination of these effects. In humans, moderate alcohol intake is associated with increased serum estrogen in post-menopausal women [215, 234-237]. Some studies show that moderate alcohol intake is linked to increased serum estrogens in men and pre-menopausal women [70, 238]; whereas, other studies have reported no differences in serum estrogen levels in pre-menopausal women [239] or middle-aged men or postmenopausal women [219]. Acute alcohol administration results in increased plasma estradiol within 25 minutes of administration [240, 241], suggesting that alcohol might acutely induce changes in hormone levels that affect bone. Thus, alcohol-

induced increase in serum estrogen may in part explain the beneficial skeletal effects of moderate alcohol consumption.

Voluntary alcohol self-administration in cynomolgus monkeys has been demonstrated to alter the expression and activity of several neurological factors including gamma-aminobutyric acid receptors [242-245], ionotropic glutamate receptor complex subunits (e.g. *N*-methyl-*D*-aspartate receptors) [246, 247], and serotonin receptors [248], all of which have been shown to influence bone remodeling [249]. Furthermore, alcohol abuse in cynomolgus monkeys has been associated with altered activity and levels of stress-related proteins, including adrenocorticotrophic hormone, cortisol, nuclear factor  $\kappa$ -light-chain-enhancer of activated B cells, and Janus kinase/signal transducer and activator of transcription [250, 251], all of which also are involved in regulation of bone remodeling [252-254].

Overall, it is likely that alcohol does not affect bone through any one mechanism, but rather through multiple mechanisms simultaneously. The effects of alcohol on bone are likely due to the concentration, duration, and rate of ethanol consumption. Factors such as the amount and composition of foods present in the gastrointestinal tract with imbibed alcohol can affect cellular exposure to alcohol independent of the volume of alcohol consumed.

## **2.7 Purpose and Hypothesis**

The purpose of the present study was to investigate the effects of alcohol abuse on bone mass, bone microarchitecture, and intracortical bone remodeling. Our hypothesis was that one year of voluntary alcohol consumption would be associated lower bone mass, altered bone microarchitecture, and reduced intracortical bone remodeling in a non-human primate model for alcohol abuse.

Table 2.1 Summary of Animal Studies Investigating the Skeletal Effects of Alcohol

| Paper                           | Model                | Sex | Quantity of Ethanol                 | Administration Method   | Duration    | Start Age   |
|---------------------------------|----------------------|-----|-------------------------------------|-------------------------|-------------|-------------|
| Broulik <i>et al</i> , 2009     | Rat (Valaz Prague)   | M   | 7.6 g/kg/day                        | Drinking water          | 3 mo        | 2 mo        |
| Callaci <i>et al</i> , 2006     | Rat (Sprague-Dawley) | F   | 3 g/kg/d for 3 consec d/wk          | IP injection            | 2 or 4 wk   | Unspecified |
| Callaci <i>et al</i> , 2008     | Rat (Sprague-Dawley) | M   | 3 g/kg/d for 3 consec d/wk          | IP injection            | 1 or 4 wk   | 16 wk       |
| Callaci <i>et al</i> , 2009     | Rat (Sprague-Dawley) | M   | 3 g/kg/d for 3 consec d/wk          | IP injection            | 1 or 4 wk   | 7 wk        |
| Chakkalakal <i>et al</i> , 2002 | Rat (Sprague-Dawley) | M   | 36% of calories                     | Liquid diet             | 13 wk       | 8-10 wk     |
| Chakkalakal <i>et al</i> , 2005 | Rat (Wistar)         | M   | 26 or 36% of calories               | Liquid diet             | 13 wk       | 11-12 wk    |
| Dai <i>et al</i> , 2000         | Mouse (C57BL/6)      | M   | 26% or calories                     | Liquid diet             | 4 mo        | 8 wk        |
| Elmali <i>et al</i> , 2002      | Rat (Wistar)         | M   | 17 g/kg/day                         | Liquid diet             | 8 wk        | Unspecified |
| Himes <i>et al</i> , 2008       | Rat (Sprague-Dawley) | M   | 3 g/kg/d for 3 consec d/wk          | IP injection            | 4 wk        | 16 wk       |
| Hogan <i>et al</i> , 2001       | Rat (Sprague-Dawley) | F   | 35% of calories                     | Liquid diet             | 8 or 14 wk  | 9 mo        |
| Howe <i>et al</i> , 2010        | Rat (Sprague-Dawley) | M   | 35% of calories                     | Liquid diet             | 6 wk        | 3 mo        |
| Irie <i>et al</i> , 2008        | Rat (Wistar)         | M   | 36% of calories                     | Liquid diet             | 4 wk        | 10 wk       |
| Iwaniec <i>et al</i> , 2008     | Rat (Sprague-Dawley) | M   | 35% of calories                     | Liquid diet             | 6 wk        | 3 mo        |
| Lauing <i>et al</i> , 2008      | Rat (Sprague-Dawley) | M   | 3 g/kg/d for 3 consec d/wk          | IP injection            | 1 or 4 wk   | 7 wks       |
| Lima <i>et al</i> , 2010        | Rat (Wistar)         | M   | 30.3±1.5 mL/d of 15% (v/v)          | Drinking water          | 90 d        | 45 d        |
| Maddalozzo <i>et al</i> , 2008  | Rat (Sprague-Dawley) | M   | 35% of calories                     | Liquid diet             | 6 wk        | 10 wk       |
| Maurel <i>et al</i> , 2011      | Rat (Wistar)         | M   | 18±3 mL/d of 35% (v/v)              | Drinking water          | 19 wk       | 8 wk        |
| Nyquist <i>et al</i> , 2002     | Rat (Sprague-Dawley) | M   | 3.4±0.2 g/d of 15% (v/v)            | Drinking water          | 6 wk        | 70 d        |
| Perrien <i>et al</i> , 2004     | Rat (Sprague-Dawley) | M   | 12 g/kg/d                           | Total enteric nutrition | 6 wk        | 3 mo        |
| Perrien <i>et al</i> , 2002     | Rat (Sprague-Dawley) | F   | 12 g/kg/d                           | Total enteric nutrition | 6 wk        | 3 mo        |
| Rai <i>et al</i> , 2008         | Rat (Sprague-Dawley) | M   | Unspecified vol. of 20 or 30% (v/v) | IP injection            | 5 d or 6 wk | Unspecified |
| Reed <i>et al</i> , 2002        | Rat (Sprague-Dawley) | M   | 35% of calories                     | Liquid diet             | 16 wk       | 6 mo        |
| Sibonga <i>et al</i> , 2007     | Rat (Sprague-Dawley) | M   | 35% of calories                     | Liquid diet             | 16 wk       | 8 mo        |
| Trevisol <i>et al</i> , 2007    | Rat (Sprague-Dawley) | M   | 35% of calories                     | Liquid diet             | 6 wk        | 3 mo        |
| Turner <i>et al</i> , 2001      | Rat (Sprague-Dawley) | F   | 3.6, 13, or 35% of calories         | Liquid diet             | 4 mo        | 8 mo        |
| Wahl <i>et al</i> , 2006        | Mouse (C57BL/6)      | M   | 36% of calories                     | Liquid diet             | 3 mo        | 12 mo       |
| Wezeman <i>et al</i> , 2003     | Rat (Sprague-Dawley) | M/F | 36% of calories                     | Liquid diet             | 4 wk        | 30 d        |

## **3- Material & Methods**

### **3.1 Animals**

A total of 34 late adolescent/young adult (mean age 6.7 years) male rhesus macaques (*Macaca mulatta*) were used. The monkeys were born and reared in captivity at the Oregon National Primate Research Center at Oregon Health and Sciences University in Beaverton, OR. They were housed individually in quadrant cages under constant temperature (20-22 °C), humidity (65%), and a 12-h light cycle (light 0700-1900 hrs) in a room allowing visual, auditory, and olfactory contact with other monkeys. Weights were recorded weekly throughout the duration of the study. Animals used in this study were pooled from 3 cohorts of monkeys. The first cohort was sacrificed in May of 2010 (n=5 control, 8 ethanol), the second in March of 2012 (n=4 control, 8 ethanol), and the third in July of 2012 (n=4 control, 5 ethanol). All of the animals from each cohort were subjected to the same study design (see below).

### **3.2 Experimental Design**

#### **3.2.1 Induction phase:**

The experimental design is described in detail in Grant et al (2008) [255]. Briefly, animals were initially trained to self-administer food, water, and ethanol using an operant panel mounted to their cage over a period of 2 to 3 weeks. Previously alcohol-naïve monkeys were then conditioned to drink increasing doses of ethanol (4% w/v) in a step-wise fashion over 4 consecutive 30-day periods for a total of 120 days. During the first 30 days the animals drank only water. During the next 30-day period, animals drank a predetermined volume of ethanol solution corresponding to 0.5 g/kg/d ethanol, followed by volumes of ethanol corresponding to 1.0 and 1.5 g/kg/d during the 3rd and 4th 30-day periods, respectively. Monkeys were given only the option to drink ethanol until the required dose was reached, at which point animals were then only allowed to drink water. This step-wise increase in alcohol induction was done to circumvent establishment of ethanol taste-aversion.

#### **3.2.2 Voluntary drinking phase:**

Following the 120-day induction period, monkeys were given simultaneous access to both water and ethanol (4% w/v) and allowed to voluntarily self-administer ethanol and/or water for 22 h/d (1100-0900 hrs each day), 7 d/wk for 12 months.



Control animals (n=13) were allowed to self-administer a maltose-dextrin solution that was isocaloric to the ethanol solution consumed. Drinking data for all animals was recorded daily by measuring the change in the masses of water and the ethanol/maltose-dextrin solution.

The fluorochrome tetracycline hydrochloride (20 mg/kg) was administered orally (17 and 3 days) prior to sacrifice for determination of active mineralization sites and rates of bone formation. At sacrifice, the first through sixth lumbar vertebrae, the distal femora, and the tibiae/fibulae from each animal were harvested and placed directly into 70% ethanol, and stored at 4°C until analysis.

### **3.3 Dual-Energy X-Ray Absorptiometry**

Bone mineral content (BMC, g/cm), bone area (cm<sup>2</sup>) and BMD (g/cm<sup>2</sup>) in the lumbar vertebrae (LV1-4) and tibiae/fibulae (the tibiae and fibulae were analyzed together) were determined *post mortem* using a dual-energy X-ray absorptiometry scanner (DXA, Hologic Discovery A, Waltham, MA, USA) and Hologic APEX System Software, Version 3.1.1. Tibial/fibular and vertebral scans were conducted in the posterior-anterior view. The tibiae/fibulae and LV1-4 were scanned using the small animal regional high-resolution option. Quality control check was performed against the Anthropomorphic Spine Phantom and Small Animal Step Phantom provided by the manufacturer. All scans were performed and analyzed by the same individual. The coefficient of variation evaluating test-retest reliability for DXA scans in our laboratory is 1.0% for BMC, bone area, and BMD.

### **3.4 Micro Computed Tomography**

Micro computed tomography ( $\mu$ CT) was performed for nondestructive 3-dimensional analysis of cancellous and cortical bone microarchitecture [256] using a Scanco  $\mu$ CT40 scanner (Scanco Medical AG, Basserdorf, Switzerland).

The 3rd lumbar vertebral body (LV3) and right distal femur of each monkey were scanned at a voxel size of 36x36x36  $\mu$ m. In the LV3, the entire region of secondary spongiosa between the cranial and caudal growth plates was evaluated (Figure 3.1). In the distal femur, 60 slices (2.2 mm) of bone at a distance of 4 slices immediately proximal to the caudal growth plate (or growth plate remnant) in the

metaphysis and the entire region of secondary spongiosa at a distance of 4 slices immediately distal to the caudal growth plate (or growth plate remnant) in the epiphysis were evaluated (Figure 3.1). In addition to the distal femur and LV3, the right distal third of the tibia of each animal was scanned (at a voxel size of 30x30x30  $\mu\text{m}$ ). In each monkey, 66 slices (2.0 mm) of bone were evaluated in the metaphysis at a distance of 165 slices (5.0 mm) proximal to the caudal growth plate, and 33 slices (1.0 mm) of bone were analyzed in the tibial diaphysis at 1/3 of the length of the tibia measured from the distal tip of the medial malleolus to the intercondylar eminence (Figure 3.1); thus, the cortical bone region assessed by  $\mu\text{CT}$  corresponds to the histological sampling site evaluated (see below).

Cancellous bone (lumbar vertebra, distal femur, and distal tibia) was analyzed at a threshold of 175, and cortical bone (tibial diaphysis) was analyzed at a threshold of 245. Threshold values were determined empirically based on a gray scale of 0-1000. Cancellous bone measurements included: (1) the ratio of cancellous bone volume to tissue volume (%), (2) connectivity density (an indicator of the connectivity of trabeculae within a given area of bone [257]), (3) structural model index (measures whether trabeculae are more plate-like or rod-like [258]), (4) trabecular thickness (the thickness of individual trabeculae,  $\mu\text{m}$ ), (5) trabecular number (the number of trabeculae intersected by a computer-generated line drawn through the bone, 1/mm), and (6) trabecular separation (the spacing between trabeculae,  $\mu\text{m}$ ). Cortical bone measurements included: (1) cross-sectional tissue volume (cortical and marrow volume,  $\text{mm}^3$ ), (2) cortical volume ( $\text{mm}^3$ ), (3) marrow volume ( $\text{mm}^3$ ), (4) cortical thickness (mm), (5) maximum moment of inertia (an indicator of bone mechanical strength in bending,  $\text{mm}^4$ ,  $I_{\text{max}}$ ), (6) minimum moment of inertia (an indicator of bone mechanical strength in bending,  $\text{mm}^4$ ,  $I_{\text{min}}$ ), and (7) the polar moment of inertia (an indicator of bone mechanical strength in torsion,  $\text{mm}^4$ ,  $I_{\text{polar}}$ )

### 3.5 Quantitative Bone Histomorphometry

Tibial length was measured as the distance from the proximal tip of the intercondylar eminence to the distal tip of the medial malleolus. Cross-sections of the tibial diaphysis (50- $\mu\text{m}$  thick) were cut at 1/3 of the length from distal end of the tibia using an IsoMet® Low Speed Saw (Buehler, Lake Bluff, IL, USA). Sections were

ground on a roughened glass surface (using 220 grit aluminum oxide powder) to an approximate thickness of 25  $\mu\text{m}$  and assessed for (1) bone area ( $\text{mm}^2$ ) and (2) the number of open and closed osteons per bone area (See figure 3.2). Incomplete osteons were defined as open osteons (with or without label) that were visually, obviously much larger than completed (closed) osteons. Fluorochrome-based measurements of bone formation in cortical bone included: (1) the number of labeled osteons/bone area (intracortical osteons that were single or double labeled, see figure 3.2), (2) mineralizing perimeter/bone area (bone perimeter covered with double plus half single fluorochrome label normalized to bone area, %), and (3) mineral apposition rate (the distance between two fluorochrome markers that comprise a double label in an osteon divided by the 14-day interval between label administration,  $\mu\text{m}/\text{day}$ ).

All histomorphometric data were collected using an Olympus BH2 Microscope (Olympus, Shinjuku, Tokyo, Japan) equipped with an Olympus DP71 microscope digital camera (Olympus, Shinjuku, Tokyo, Japan) and attached to a computer system with OsteoMeasure software (OsteoMetrics, Atlanta, GA, USA). Bone area and the number of complete and incomplete osteons were assessed using a 2x objective, and fluorochrome-based measurements were assessed using a 4x objective.

### **3.6 Serum Measures of Bone Resorption**

Serum samples were collected from all monkeys at necropsy, and were assessed for carboxy-terminal collagen crosslinks (CTX) using Serum CrossLaps ELISA (Immunodiagnostic Systems Inc, Fountain Hills, AZ, USA)

### **3.7 Blood Alcohol Concentrations**

Blood samples were collected every 2-5 days from the saphenous vein of monkeys in the alcohol group just before the lights were turned off (between 1800 and 1900 hours). Blood samples were sealed in airtight vials containing 0.5 ml of distilled water and 0.02 mL of 10% isopropanol (internal standard), and stored at  $-4^{\circ}\text{C}$  until assayed using gas chromatography (Hewlett-Packard 5890 Series II, Avondale, PA, equipped with a headspace autosampler, flame ionization detector, and a Hewlett Packard 3392A integrator).

### **3.8 Statistical Measures**

All data are expressed as mean  $\pm$  SE. Data were analyzed with a 2-tailed *t* test using R (R Development Core Team, Vienna, Austria). A *p*-value of  $\leq 0.05$  was considered significant.




Figure 3.1 Volumes of interest in the lumbar vertebra, femur, and tibia,




Figure 3.2 Examples of incomplete (open) and complete (closed) osteons.

## 4- Results

Study population characteristics (age, weight, average alcohol consumption, and average blood alcohol concentration) in control and ethanol groups are shown in Table 4.1. Significant differences were not detected in mean age or in terminal body weight or between control and ethanol groups. Animals in the alcohol group drank an average of 2.8 g ethanol per kg body weight per day over the 12-month duration of the study resulting in blood alcohol concentrations ranging from 20 to 140 mg/dL and averaging 76.7 mg/dL. By design, animals in the control group did not consume any ethanol.

The effects of alcohol consumption on bone mass and bone microarchitecture in the lumbar vertebra are summarized in Table 4.2. Significant differences in lumbar vertebral bone area, BMC, or BMD were not detected between control and alcohol groups. Moreover, no difference was observed for any cancellous microarchitectural parameter measured in the lumbar vertebra (bone volume/tissue volume ratio, connectivity-density, structural model index, trabecular number, trabecular thickness, or trabecular separation).

The effects of alcohol consumption on cancellous bone microarchitecture in the distal femur are summarized in Table 4.3. Significant differences between control and alcohol groups were not detected for any cancellous microarchitectural parameter measured in the distal femur metaphysis or epiphysis (bone volume/tissue volume ratio, connectivity-density, structural model index, trabecular number, trabecular thickness, or trabecular separation).

The effects of alcohol consumption on bone size, bone mass, and bone microarchitecture in the tibia are summarized in Table 4.4. Significant differences between control and alcohol groups were not detected for tibia length or for tibia/fibula bone area, BMC, or BMD. Additionally, significant differences between control and alcohol groups were not observed for any cancellous microarchitectural parameter measured in the distal tibia metaphysis (bone volume/tissue volume ratio, connectivity-density, structural model index, trabecular number, trabecular thickness, or trabecular separation) or in any measured parameters of cortical bone architecture in the tibia

diaphysis (cross-sectional volume, cortical volume, marrow volume, cortical thickness,  $I_{\max}$ ,  $I_{\min}$ , or  $I_{\text{polar}}$ ).

Quantitative intracortical bone histomorphometry results are shown in Figures 4.1-4.3. The numbers of labeled osteons per bone area were significantly lower in the alcohol group than the control group (Figures 4.1 and 4.2). Additionally, the density of incomplete osteons was significantly lower in alcohol-consuming monkeys relative to controls (Figure 4.2). Significant differences in mineral apposition rate were not detected with treatment (Figure 4.3).

Serum measures of biochemical markers of bone turnover are shown in Figure 4.4. Serum CTX was significantly higher in the alcohol group compared to the control group (Figure 4.4).






Figure 4.1 Representative histological sections of the tibial diaphysis from control (left) and alcohol (right) animals.




Figure 4.2 (A) Number of labeled osteons per square millimeter of bone in control and alcohol monkeys. (B) Number of incomplete osteons per square millimeter of bone in control and alcohol monkeys. Data are mean  $\pm$  SE. \*  $P < 0.05$  compared to control.




Figure 4.3 Mineral apposition rate in control and alcohol monkeys. Data are mean  $\pm$  SE.




Figure 4.4 Serum CTX levels in alcohol and control monkeys at necropsy. Data are mean  $\pm$  SE. \*  $P < 0.05$  compared to control.

Table 4.1 Study Population

| Endpoint                           | Control   | Alcohol    | <i>t</i> test, <i>p</i> |
|------------------------------------|-----------|------------|-------------------------|
| Age (years)                        | 6.7 ± 0.3 | 6.7 ± 0.2  | 0.95                    |
| Body Weight (kg)                   | 8.5 ± 0.5 | 8.7 ± 0.2  | 0.64                    |
| 1st 6 mo avg ethanol intake (g/kg) |           | 2.5 ± 0.2  |                         |
| 2nd 6 mo avg ethanol intake (g/kg) |           | 3.0 ± 0.1  |                         |
| 12 mo avg ethanol intake (g/kg)    |           | 2.8 ± 0.1  |                         |
| 1st 6 mo avg BAC (mg/dL)           |           | 67.7 ± 7.8 |                         |
| 2nd 6 mo avg BAC (mg/dL)           |           | 81.6 ± 9.2 |                         |
| 12 mo avg BAC (mg/dL)              |           | 76.7 ± 8.8 |                         |

*Data are mean ± SE, BAC = Blood Alcohol Concentrations*

Table 4.2 Effects of Alcohol on Bone in the Lumbar Vertebrae

| Endpoint                                  | Control     | Alcohol      | <i>t</i> test, <i>p</i> |
|---|-------------|--------------|-------------------------|
| Lumbar Vertebra 1-4                       |             |              |                         |
| Bone Area (cm <sup>2</sup> )              | 18.8 ± 1.3  | 17.3 ± 1.3   | 0.83                    |
| BMC (g)                                   | 5.11 ± 0.55 | 5.35 ± 0.50  | 0.75                    |
| BMD (g/cm <sup>2</sup> )                  | 1.54 ± 0.13 | 1.44 ± 0.16  | 0.82                    |
| 3rd Lumbar Vertebra (Cancellous Bone)     |             |              |                         |
| Bone Volume/Tissue Volume (%)             | 21.4 ± 0.6  | 19.9 ± 1     | 0.19                    |
| Connectivity-density (1/mm <sup>2</sup> ) | 9.96 ± 0.68 | 10.24 ± 0.53 | 0.74                    |
| Structural Model Index                    | 0.98 ± 0.09 | 1.15 ± 0.08  | 0.16                    |
| Trabecular Number (1/mm)                  | 1.5 ± 0.0   | 1.5 ± 0.0    | 0.97                    |
| Trabecular Thickness (µm)                 | 148 ± 3     | 140 ± 4      | 0.11                    |
| Trabecular Separation (µm)                | 631 ± 17    | 635 ± 15     | 0.87                    |

*Data are mean ± SE, BMC = Bone Mineral Content, BMD = Bone Mineral Density*

Table 4.3 Effects of Alcohol on Bone in the Femur

| Endpoint                                  | Control     | Alcohol     | <i>t</i> test, <i>p</i> |
|---|-------------|-------------|-------------------------|
| Distal Femur Epiphysis (cancellous bone)  |             |             |                         |
| Bone Volume/Tissue Volume (%)             | 29.7 ± 1.2  | 29.9 ± 1.1  | 0.95                    |
| Connectivity-density (1/mm <sup>2</sup> ) | 7.53 ± 0.91 | 7.73 ± 1.10 | 0.89                    |
| Structural Model Index                    | 0.09 ± 0.15 | 0.04 ± 0.12 | 0.80                    |
| Trabecular Number (1/mm)                  | 1.7 ± 0.1   | 1.7 ± 0.1   | 0.91                    |
| Trabecular Thickness (µm)                 | 193 ± 10    | 187 ± 6     | 0.63                    |
| Trabecular Separation (µm)                | 569 ± 34    | 564 ± 26    | 0.91                    |
| Distal Femur Metaphysis (cancellous bone) |             |             |                         |
| Bone Volume/Tissue Volume (%)             | 18.8 ± 1.3  | 17.3 ± 1.3  | 0.83                    |
| Connectivity-density (1/mm <sup>2</sup> ) | 5.11 ± 0.55 | 5.35 ± 0.50 | 0.75                    |
| Structural Model Index                    | 1.54 ± 0.13 | 1.44 ± 0.16 | 0.82                    |
| Trabecular Number (1/mm)                  | 1.4 ± 0.1   | 1.5 ± 0.1   | 0.80                    |
| Trabecular Thickness (µm)                 | 164 ± 9     | 160 ± 5     | 0.65                    |
| Trabecular Separation (µm)                | 710 ± 31    | 710 ± 32    | 0.99                    |

*Data are mean ± SE*

Table 4.4 Effects of Alcohol on Bone in the Tibia

| Endpoint                                  | Control     | Alcohol     | <i>t</i> test, <i>p</i> |
|---|-------------|-------------|-------------------------|
| Tibia Length (mm)                         | 168 ± 2     | 172 ± 1     | 0.15                    |
| Tibia/fibula                              |             |             |                         |
| Bone Area (cm <sup>2</sup> )              | 28.1 ± 0.7  | 27.2 ± 0.5  | 0.33                    |
| BMC (g)                                   | 11.0 ± 0.6  | 10.1 ± 0.4  | 0.22                    |
| BMD (g/cm <sup>2</sup> )                  | 0.39 ± 0.01 | 0.37 ± 0.01 | 0.21                    |
| Tibia Diaphysis (cortical bone)           |             |             |                         |
| Cross-Sectional Volume (mm <sup>3</sup> ) | 78.0 ± 3.2  | 78.2 ± 2.4  | 0.96                    |
| Cortical Volume (mm <sup>3</sup> )        | 52.5 ± 2.5  | 51.7 ± 1.3  | 0.78                    |
| Marrow Volume (mm <sup>3</sup> )          | 25.5 ± 1.9  | 26.5 ± 1.9  | 0.71                    |
| Cortical Thickness (mm)                   | 2.10 ± 0.86 | 2.07 ± 0.63 | 0.82                    |
| I <sub>max</sub> (mm <sup>4</sup> )       | 564 ± 55    | 559 ± 31    | 0.94                    |
| I <sub>min</sub> (mm <sup>4</sup> )       | 330 ± 23    | 328 ± 20    | 0.94                    |
| I <sub>polar</sub> (mm <sup>4</sup> )     | 894 ± 77    | 887 ± 50    | 0.94                    |
| Distal Tibia Metaphysis (cancellous bone) |             |             |                         |
| Bone Volume/Tissue Volume (%)             | 20.7 ± 1.5  | 20.8 ± 1.4  | 0.92                    |
| Connectivity-density (1/mm <sup>2</sup> ) | 6.45 ± 0.64 | 6.02 ± 0.48 | 0.60                    |
| Structural Model Index                    | 1.13 ± 0.12 | 1.03 ± 0.12 | 0.54                    |
| Trabecular Number (1/mm)                  | 1.6 ± 0.1   | 1.5 ± 0.1   | 0.56                    |
| Trabecular Thickness (μm)                 | 163 ± 6     | 165 ± 6     | 0.81                    |
| Trabecular Separation (μm)                | 629 ± 35    | 645 ± 21    | 0.70                    |

*Data are mean ± SE, BMC = Bone Mineral Content, BMD = Bone Mineral Density*



## 5- Discussion

In this study we examined the effects of 12 months of voluntary self-administration of alcohol on bone mass, microarchitecture, and turnover in male rhesus monkeys. To the best of our knowledge, this is the first study to examine the effects of alcohol abuse on indices of intracortical bone remodeling in an animal model. An average consumption of  $2.8 \pm 0.1$  g/kg/d ethanol, resulting in 12-month average blood alcohol concentrations of  $76.7 \pm 9$  mg/dL (0.07%), had no effect on bone mass or bone microarchitecture; however, alcohol consuming animals exhibited markedly lower histological indices of intracortical bone resorption and formation, as well as a significantly lower biochemical marker of global bone resorption. Therefore, our data indicates that 12 months of alcohol abuse significantly depresses intracortical bone remodeling without having significant effects on bone mass or microarchitecture.

Our findings are consistent with the general consensus that alcohol abuse reduces biochemical markers bone formation in humans [58, 71, 73, 74, 90-93]. Even moderate alcohol consumption has been reported to significantly decrease serum indicators of bone formation [65, 67]. However, biochemical indices of bone remodeling are not specific to either cancellous or cortical bone. Histomorphometric analysis of bone biopsies allows for accurate assessment of both cortical and cancellous bone formation. Analyses of human transiliac biopsies have associated alcohol abuse with reduced histological indices of cancellous bone formation [76, 86-89]; however, to the best of our knowledge no study in humans has investigated the effects of alcohol on bone remodeling at any skeletal site other than the iliac crest, and only one study in humans has reported the effects of alcohol on indices of intracortical bone remodeling [89]. In a study by Schnitzler et al (2010), analysis of transiliac biopsies from 16 male alcoholic patients with chronic pancreatitis showed that alcohol abuse was associated with lower endocortical osteoid surface, mineral apposition rate, and bone formation rate and a greater amount of endocortical eroded surface; however, no effects of alcohol were observed on osteonal osteoid thickness or surface, eroded surface, mineral apposition rate, or osteonal bone formation rate [89]. These results are not consistent with the findings of our study. Although we cannot be certain that the inconsistency is not due to species differences, other explanations seem more likely; for example, the influence of the presence of multiple comorbidities including type II

diabetes and chronic pancreatitis in these patients could help explain these differences. Pancreatitis is associated with nutrient malabsorption, low serum vitamin D levels, and alcohol-independent effects on bone mass in humans [259]. The monkeys in the present study did not suffer from notable comorbidities. Moreover, the location of the cortical bone analyzed might explain incongruence between results, as cortical bone at the iliac crest is not subjected to the same amount of mechanical loading as cortical bone at the tibial diaphysis.

Reports regarding the effects of alcohol consumption on bone resorption are less consistent, with studies in human alcoholics reporting lower [86], higher [87, 90, 92, 94], or no difference [76] in resorption. In our study, we observed marked reductions in the number of incomplete osteons in tibial diaphyseal cortical bone of alcohol-consuming animals, suggesting that intracortical bone resorption is significantly decreased with alcohol. This conclusion is supported by our finding of lower serum biomarkers of resorption (CTX) in alcohol-consuming animals. Since bone formation is generally coupled to bone resorption, it is possible that these alcohol-induced reductions in intracortical bone resorption might contribute to the decreased intracortical bone formation observed in our study.

Numerous observational and case-control studies in alcoholics have associated chronic alcohol abuse with lower BMD and BMC [57, 71-78], as well as altered parameters of cancellous bone microarchitecture at the iliac crest [89]. However, in many of these studies subjects had numerous alcoholism-related comorbidities that could have alcohol-independent skeletal effects (such as liver or kidney disease, smoking tobacco, or other comorbidities). Laitinen et al (1993) reported that an average consumption of  $186 \pm 85$  g/d (~13 drinks/d) in women (mean age  $38 \pm 6$  years) without cirrhosis had no effect on BMD [58]. This finding is consistent with our results and suggests that in an otherwise healthy individual, heavy alcohol consumption does not necessarily affect bone mass or bone microarchitecture.

Rodent models of chronic alcohol abuse have also associated heavy alcohol consumption with reduced bone mass [96-98, 101, 103, 104, 136, 153] and abnormal cortical and cancellous bone microarchitecture [96, 97, 103, 140]. However, most

studies in rodents have been done in rapidly growing, skeletally immature animals. The monkeys in this study are at or near skeletal maturity, thus they model young adult humans. Hence, the negative effects of alcohol administration on bone mass and architecture observed in studies in rodents occur at least in part through different physiological processes (reduced gain of bone rather than loss of bone). Skeletally mature rats also exhibit lower bone mass and altered bone architecture with administration of alcohol-containing liquid diets compared to animals consuming liquid diets *ad libitum* [100, 135, 144]. However, when skeletally mature control rats are pair-fed to alcohol-consuming rats, differences in bone mass and microarchitecture between alcohol and control rats are much smaller compared to rats that are *ad libitum* fed [144], and significant differences do not appear until after a longer duration of time [144]. Moreover, even when control rats are pair fed, animals in the alcohol group sometimes have smaller body weights compared to controls [135, 144]. In the present study, no significant difference was observed in the body weight of monkeys in the control group compared to the alcohol group.

The cellular and molecular mechanisms underlying the effects of alcohol on bone are not fully understood, and it is likely that alcohol acts on bone through the combination of a number of mechanisms, both direct and indirect (see Maurel et al (2012) for a more in depth review of the mechanisms of alcohol on bone [260]). There is evidence from cell culture studies that high concentrations of ethanol can directly affect osteoblasts, osteoclasts, and osteocytes. Furthermore, alcohol has been shown to act as an endocrine disruptor, altering levels of and skeletal response to sex hormones (e.g. estrogen and testosterone), vitamin D, and parathyroid hormone, as well as influencing the skeletal effects of pituitary (e.g. growth hormone) and adipocyte (e.g. leptin) derived hormones. Given the striking effects of alcohol on intracortical bone remodeling observed in the present study, further investigation into the cellular mechanisms of these effects is warranted in future studies.

Our study has several limitations of note. First, our study design lacks the ability to determine a molecular mechanism through which alcohol may reduce bone turnover. Second, although reduced bone remodeling during the period when animals are reaching skeletal maturity would suggest reduced bone quality (and possible impaired

peak bone mass accrual), which would indicate increased fracture risk, our study did not directly investigate the effects of alcohol abuse on the mechanical properties of bone. Our study does however have several notable strengths. The pattern of alcohol abuse exhibited by the monkeys in this study recapitulates patterns of alcohol abuse in humans. As reported in cynomolgus monkeys under the same alcohol treatment protocol [255], given 22 h/d open access to ethanol (4% w/v) and water, monkeys frequently engaged in episodes of spree (or binge) drinking during which the animals would “gulp” rather than “sip” alcohol. Also, blood alcohol concentrations were highly variable within each animal, with intra-individual variations of 0 to 300 mg/dL on different days (data not shown). The patterns of alcohol consumption and blood alcohol concentrations in the monkeys within this study are remarkably similar to drinking patterns and blood alcohol concentrations of alcoholic men given 24 h/d free access to ethanol for 10-60 consecutive days in a hospital ward [261-263]. Finally, our study allows for the assessment of the effects of alcohol on intracortical bone remodeling in a weight bearing skeletal site.

## **6- Conclusions**

The results of the present study indicate that 12 months of voluntary alcohol abuse in male rhesus monkeys does not have significant effects on bone mass or bone microarchitecture; however, this pattern and duration of alcohol abuse did result in significantly reduced intracortical bone turnover. Reduced bone turnover could contribute to deficient repair of microfractures accrued during activities of daily living and lead to reduced bone mechanical properties independent of bone mass or microarchitecture, which could contribute to increased bone fracture risk. Further studies are required to evaluate the effects of alcohol on bone quality in cortical bone.

## Bibliography

1. Burge, R., et al., *Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025*. J Bone Miner Res, 2007. **22**(3): p. 465-75.
2. Viswanathan, H.N., et al., *Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy*. Appl Health Econ Health Policy, 2012. **10**(3): p. 163-73.
3. Johnell, O. and J.A. Kanis, *An estimate of the worldwide prevalence and disability associated with osteoporotic fractures*. Osteoporos Int, 2006. **17**(12): p. 1726-33.
4. MacLean, C., et al., *Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis*. Ann Intern Med, 2008. **148**(3): p. 197-213.
5. Dempster, D.W., *Osteoporosis and the burden of osteoporosis-related fractures*. Am J Manag Care, 2011. **17 Suppl 6**: p. S164-9.
6. Cooke, A.M., *Osteoporosis*. Lancet, 1955. **268**(6871): p. 929-37.
7. Robling, A.G., A.B. Castillo, and C.H. Turner, *Biomechanical and molecular regulation of bone remodeling*. Annu Rev Biomed Eng, 2006. **8**: p. 455-98.
8. Nguyen, T.V. and J.A. Eisman, *Genetic profiling and individualized assessment of fracture risk*. Nat Rev Endocrinol, 2013. **9**(3): p. 153-61.
9. Michou, L. and J.P. Brown, *Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta*. Joint Bone Spine, 2011. **78**(3): p. 252-8.
10. Gratacos, J., et al., *Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study*. Arthritis Rheum, 1999. **42**(11): p. 2319-24.
11. Schett, G. and E. Gravallese, *Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment*. Nat Rev Rheumatol, 2012. **8**(11): p. 656-64.
12. Lilleby, V., *Bone status in juvenile systemic lupus erythematosus*. Lupus, 2007. **16**(8): p. 580-6.
13. Weinstock-Guttman, B., et al., *Risk of bone loss in men with multiple sclerosis*. Mult Scler, 2004. **10**(2): p. 170-5.
14. Selby, P.L., et al., *Bone loss in celiac disease is related to secondary hyperparathyroidism*. J Bone Miner Res, 1999. **14**(4): p. 652-7.
15. Lobao, R., et al., *High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis*. Clin Nephrol, 2004. **62**(6): p. 432-9.
16. Diamond, T.H., et al., *Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease*. Gastroenterology, 1989. **96**(1): p. 213-21.
17. White, S.L., et al., *Alcohol consumption and 5-year onset of chronic kidney disease: the AusDiab study*. Nephrol Dial Transplant, 2009. **24**(8): p. 2464-72.
18. Compston, J.E., *Bone: Risk of osteoporotic fractures in irritable bowel syndrome*. Nat Rev Endocrinol, 2013. **9**(1): p. 8-9.
19. Cashman, K.D., *Diet, nutrition, and bone health*. J Nutr, 2007. **137**(11 Suppl): p. 2507S-2512S.

20. Holick, M.F., *Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease*. Am J Clin Nutr, 2004. **80**(6 Suppl): p. 1678S-88S.
21. Mitra, R., *Adverse effects of corticosteroids on bone metabolism: a review*. PM R, 2011. **3**(5): p. 466-71; quiz 471.
22. Bielemann, R.M., J. Martinez-Mesa, and D.P. Gigante, *Physical activity during life course and bone mass: a systematic review of methods and findings from cohort studies with young adults*. BMC Musculoskelet Disord, 2013. **14**: p. 77.
23. Janz, K.F., et al., *Early physical activity provides sustained bone health benefits later in childhood*. Med Sci Sports Exerc, 2010. **42**(6): p. 1072-8.
24. Meyer, U., et al., *3-year follow-up results of bone mineral content and density after a school-based physical activity randomized intervention trial*. Bone, 2013. **55**(1): p. 16-22.
25. Kanis, J.A., et al., *Smoking and fracture risk: a meta-analysis*. Osteoporos Int, 2005. **16**(2): p. 155-62.
26. Rapuri, P.B., et al., *Smoking and bone metabolism in elderly women*. Bone, 2000. **27**(3): p. 429-36.
27. Wong, P.K., J.J. Christie, and J.D. Wark, *The effects of smoking on bone health*. Clin Sci (Lond), 2007. **113**(5): p. 233-41.
28. Schiller, J.S., et al., *Summary health statistics for U.S. adults: National Health Interview Survey, 2010*. Vital Health Stat 10, 2012(252): p. 1-207.
29. Grant, B.F., et al., *The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002*. Drug Alcohol Depend, 2004. **74**(3): p. 223-34.
30. Baer, D.J., et al., *Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet*. Am J Clin Nutr, 2002. **75**(3): p. 593-9.
31. Gaziano, J.M., et al., *Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction*. N Engl J Med, 1993. **329**(25): p. 1829-34.
32. Pellegrini, N., et al., *Effects of moderate consumption of red wine on platelet aggregation and haemostatic variables in healthy volunteers*. Eur J Clin Nutr, 1996. **50**(4): p. 209-13.
33. Puddey, I.B., et al., *Evidence for a direct effect of alcohol consumption on blood pressure in normotensive men. A randomized controlled trial*. Hypertension, 1985. **7**(5): p. 707-13.
34. Davies, M.J., et al., *Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial*. JAMA, 2002. **287**(19): p. 2559-62.
35. Bonnet, F., et al., *Moderate alcohol consumption is associated with improved insulin sensitivity, reduced basal insulin secretion rate and lower fasting glucagon concentration in healthy women*. Diabetologia, 2012. **55**(12): p. 3228-37.
36. Hong, J., et al., *Alcohol consumption promotes insulin sensitivity without affecting body fat levels*. Int J Obes (Lond), 2009. **33**(2): p. 197-203.
37. Agarwal, D.P., *Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms*. Alcohol Alcohol, 2002. **37**(5): p. 409-15.

38. Langer, R.D., M.H. Criqui, and D.M. Reed, *Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease*. *Circulation*, 1992. **85**(3): p. 910-5.
39. Berger, K., et al., *Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians*. *N Engl J Med*, 1999. **341**(21): p. 1557-64.
40. Sacco, R.L., et al., *The protective effect of moderate alcohol consumption on ischemic stroke*. *JAMA*, 1999. **281**(1): p. 53-60.
41. Baliunas, D.O., et al., *Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis*. *Diabetes Care*, 2009. **32**(11): p. 2123-32.
42. Koppes, L.L., et al., *Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies*. *Diabetes Care*, 2005. **28**(3): p. 719-25.
43. Rimm, E.B., et al., *Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men*. *BMJ*, 1995. **310**(6979): p. 555-9.
44. Ganguli, M., et al., *Alcohol consumption and cognitive function in late life: a longitudinal community study*. *Neurology*, 2005. **65**(8): p. 1210-7.
45. Mukamal, K.J., et al., *Prospective study of alcohol consumption and risk of dementia in older adults*. *JAMA*, 2003. **289**(11): p. 1405-13.
46. Stampfer, M.J., et al., *Effects of moderate alcohol consumption on cognitive function in women*. *N Engl J Med*, 2005. **352**(3): p. 245-53.
47. Rostron, B., *Alcohol consumption and mortality risks in the USA*. *Alcohol Alcohol*, 2012. **47**(3): p. 334-9.
48. Di Castelnuovo, A., et al., *Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies*. *Arch Intern Med*, 2006. **166**(22): p. 2437-45.
49. Rehm, J., C.T. Sempos, and M. Trevisan, *Alcohol and cardiovascular disease--more than one paradox to consider. Average volume of alcohol consumption, patterns of drinking and risk of coronary heart disease--a review*. *J Cardiovasc Risk*, 2003. **10**(1): p. 15-20.
50. Kelly, J.P., et al., *Alcohol consumption and the risk of major upper gastrointestinal bleeding*. *Am J Gastroenterol*, 1995. **90**(7): p. 1058-64.
51. Cook, R.T., *Alcohol abuse, alcoholism, and damage to the immune system--a review*. *Alcohol Clin Exp Res*, 1998. **22**(9): p. 1927-42.
52. Harper, C., *The neuropathology of alcohol-specific brain damage, or does alcohol damage the brain?* *J Neuropathol Exp Neurol*, 1998. **57**(2): p. 101-10.
53. Fahrner, E.M., *Sexual dysfunction in male alcohol addicts: prevalence and treatment*. *Arch Sex Behav*, 1987. **16**(3): p. 247-57.
54. McGregor, S.E., et al., *Case-control study of lifetime alcohol intake and prostate cancer risk*. *Cancer Causes Control*, 2013. **24**(3): p. 451-61.
55. Breslow, R.A., et al., *Prospective study of alcohol consumption quantity and frequency and cancer-specific mortality in the US population*. *Am J Epidemiol*, 2011. **174**(9): p. 1044-53.
56. Regier, D.A., et al., *Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study*. *JAMA*, 1990. **264**(19): p. 2511-8.



57. Malik, P., et al., *Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study*. Alcohol Clin Exp Res, 2009. **33**(2): p. 375-81.
58. Laitinen, K., et al., *Is alcohol an osteoporosis-inducing agent for young and middle-aged women?* Metabolism, 1993. **42**(7): p. 875-81.
59. Wosje, K.S. and H.J. Kalkwarf, *Bone density in relation to alcohol intake among men and women in the United States*. Osteoporos Int, 2007. **18**(3): p. 391-400.
60. Felson, D.T., et al., *Alcohol intake and bone mineral density in elderly men and women. The Framingham Study*. Am J Epidemiol, 1995. **142**(5): p. 485-92.
61. Ganry, O., C. Baudoin, and P. Fardellone, *Effect of alcohol intake on bone mineral density in elderly women: The EPIDOS Study*. Epidemiologie de l'Osteoporose. Am J Epidemiol, 2000. **151**(8): p. 773-80.
62. Holbrook, T.L. and E. Barrett-Connor, *A prospective study of alcohol consumption and bone mineral density*. BMJ, 1993. **306**(6891): p. 1506-9.
63. Ilich, J.Z., et al., *To drink or not to drink: how are alcohol, caffeine and past smoking related to bone mineral density in elderly women?* J Am Coll Nutr, 2002. **21**(6): p. 536-44.
64. Laitinen, K., et al., *Effects of 3 weeks' moderate alcohol intake on bone and mineral metabolism in normal men*. Bone Miner, 1991. **13**(2): p. 139-51.
65. Marrone, J.A., et al., *Moderate alcohol intake lowers biochemical markers of bone turnover in postmenopausal women*. Menopause, 2012. **19**(9): p. 974-9.
66. Mukamal, K.J., et al., *Alcohol consumption, bone density, and hip fracture among older adults: the cardiovascular health study*. Osteoporos Int, 2007. **18**(5): p. 593-602.
67. Rapuri, P.B., et al., *Alcohol intake and bone metabolism in elderly women*. Am J Clin Nutr, 2000. **72**(5): p. 1206-13.
68. Sommer, I., et al., *Alcohol consumption and bone mineral density in elderly women*. Public Health Nutr, 2013. **16**(4): p. 704-12.
69. Tucker, K.L., et al., *Effects of beer, wine, and liquor intakes on bone mineral density in older men and women*. Am J Clin Nutr, 2009. **89**(4): p. 1188-96.
70. Venkat, K.K., et al., *Effect of alcohol consumption on bone mineral density and hormonal parameters in physically active male soldiers*. Bone, 2009. **45**(3): p. 449-54.
71. Alvisa-Negrin, J., et al., *Osteopenia in alcoholics: effect of alcohol abstinence*. Alcohol Alcohol, 2009. **44**(5): p. 468-75.
72. Gonzalez-Reimers, E., et al., *Prognosis of osteopenia in chronic alcoholics*. Alcohol, 2011. **45**(3): p. 227-38.
73. Gonzalez-Reimers, E., et al., *Vitamin D and nutritional status are related to bone fractures in alcoholics*. Alcohol Alcohol, 2011. **46**(2): p. 148-55.
74. Santolaria, F., et al., *Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients*. Alcohol, 2000. **22**(3): p. 147-57.
75. Kouda, K., et al., *Alcohol intake and bone status in elderly Japanese men: baseline data from the Fujiwara-kyo osteoporosis risk in men (FORMEN) study*. Bone, 2011. **49**(2): p. 275-80.
76. Diamond, T., et al., *Ethanol reduces bone formation and may cause osteoporosis*. Am J Med, 1989. **86**(3): p. 282-8.
77. Kim, M.J., et al., *Effect of chronic alcohol ingestion on bone mineral density in males without liver cirrhosis*. Korean J Intern Med, 2003. **18**(3): p. 174-80.

78. Santori, C., et al., *Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol*. J Endocrinol Invest, 2008. **31**(4): p. 321-6.
79. Gonzalez-Reimers, E., et al., *Rib fractures in chronic alcoholic men: Relationship with feeding habits, social problems, malnutrition, bone alterations, and liver dysfunction*. Alcohol, 2005. **37**(2): p. 113-7.
80. Hoidrup, S., et al., *Alcohol intake, beverage preference, and risk of hip fracture in men and women*. Copenhagen Centre for Prospective Population Studies. Am J Epidemiol, 1999. **149**(11): p. 993-1001.
81. Hui, S.L., C.W. Slemenda, and C.C. Johnston, Jr., *Age and bone mass as predictors of fracture in a prospective study*. J Clin Invest, 1988. **81**(6): p. 1804-9.
82. Hui, S.L., C.W. Slemenda, and C.C. Johnston, Jr., *Baseline measurement of bone mass predicts fracture in white women*. Ann Intern Med, 1989. **111**(5): p. 355-61.
83. Riis, B.J., et al., *Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study*. Bone, 1996. **19**(1): p. 9-12.
84. Ross, P.D., et al., *Pre-existing fractures and bone mass predict vertebral fracture incidence in women*. Ann Intern Med, 1991. **114**(11): p. 919-23.
85. Kanis, J.A., et al., *Alcohol intake as a risk factor for fracture*. Osteoporos Int, 2005. **16**(7): p. 737-42.
86. Bikle, D.D., et al., *Alcohol-induced bone disease: relationship to age and parathyroid hormone levels*. Alcohol Clin Exp Res, 1993. **17**(3): p. 690-5.
87. Chappard, D., et al., *Alcoholic cirrhosis and osteoporosis in men: a light and scanning electron microscopy study*. J Stud Alcohol, 1991. **52**(3): p. 269-74.
88. Crilly, R.G., et al., *Bone histomorphometry, bone mass, and related parameters in alcoholic males*. Calcif Tissue Int, 1988. **43**(5): p. 269-76.
89. Schnitzler, C.M., J.M. Mesquita, and R. Shires, *Cortical and trabecular bone microarchitecture and turnover in alcohol-induced chronic pancreatitis: a histomorphometric study*. J Bone Miner Metab, 2010. **28**(4): p. 456-67.
90. Diez, A., et al., *Alcohol-induced bone disease in the absence of severe chronic liver damage*. J Bone Miner Res, 1994. **9**(6): p. 825-31.
91. Malik, P., et al., *Markers of bone resorption and formation during abstinence in male alcoholic patients*. Alcohol Clin Exp Res, 2012. **36**(12): p. 2059-64.
92. Nyquist, F., et al., *Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics*. Bone, 1996. **19**(1): p. 51-4.
93. Labib, M., et al., *Bone disease in chronic alcoholism: the value of plasma osteocalcin measurement*. Alcohol Alcohol, 1989. **24**(2): p. 141-4.
94. Pepersack, T., et al., *Longitudinal study of bone metabolism after ethanol withdrawal in alcoholic patients*. J Bone Miner Res, 1992. **7**(4): p. 383-7.
95. Dai, J., et al., *Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice*. J Clin Invest, 2000. **106**(7): p. 887-95.
96. Maddalozzo, G.F., et al., *Alcohol alters whole body composition, inhibits bone formation, and increases bone marrow adiposity in rats*. Osteoporos Int, 2009. **20**(9): p. 1529-38.
97. Maurel, D.B., et al., *Low bone accrual is associated with osteocyte apoptosis in alcohol-induced osteopenia*. Bone, 2011. **49**(3): p. 543-52.
98. Nyquist, F., et al., *Effects of alcohol on bone mineral and mechanical properties of bone in male rats*. Alcohol Alcohol, 2002. **37**(1): p. 21-4.

99. Hogan, H.A., et al., *Alcohol consumption by young actively growing rats: a study of cortical bone histomorphometry and mechanical properties*. Alcohol Clin Exp Res, 1997. **21**(5): p. 809-16.
100. Turner, R.T., et al., *Moderate alcohol consumption suppresses bone turnover in adult female rats*. J Bone Miner Res, 2001. **16**(3): p. 589-94.
101. Broulik, P.D., et al., *The effect of chronic alcohol administration on bone mineral content and bone strength in male rats*. Physiol Res, 2010. **59**(4): p. 599-604.
102. Rai, D.V., et al., *Acute and chronic dose of alcohol affect the load carrying capacity of long bone in rats*. J Biomech, 2008. **41**(1): p. 20-4.
103. Wezeman, F.H., et al., *Chronic alcohol consumption during male rat adolescence impairs skeletal development through effects on osteoblast gene expression, bone mineral density, and bone strength*. Alcohol Clin Exp Res, 1999. **23**(9): p. 1534-42.
104. Wezeman, F.H., et al., *Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat*. J Bone Miner Res, 2000. **15**(10): p. 2033-41.
105. Clarke, B., *Normal bone anatomy and physiology*. Clin J Am Soc Nephrol, 2008. **3 Suppl 3**: p. S131-9.
106. Burr, D.B., *Estimated intracortical bone turnover in the femur of growing macaques: implications for their use as models in skeletal pathology*. Anat Rec, 1992. **232**(2): p. 180-9.
107. Burr, D.B., et al., *Bone microdamage and skeletal fragility in osteoporotic and stress fractures*. J Bone Miner Res, 1997. **12**(1): p. 6-15.
108. Hanson, D.J., *Preventing Alcohol Abuse: Alcohol, Culture, and Control*. 1995, Westport, CT: Greenwood Publishing Group. 140.
109. CDC. *What is a Standard Drink in the United States*. 2012 [cited 7/4/2013; Available from: <http://www.cdc.gov/alcohol/faqs.htm#standDrink>].
110. McGuire, S., *U.S. Department of Agriculture and U.S. Department of Health and Human Services, Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing Office, January 2011*. Adv Nutr, 2011. **2**(3): p. 293-4.
111. ICAP. *What Is a "Standard Drink"?* 1998 [cited 7/4/2013; Available from: <http://www.icap.org/LinkClick.aspx?fileticket=zo2TZaGGEoQ=>].
112. SAMHSA, *Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, 2012*, U.S. Department of Health and Human Services: Rockville, MD.
113. Centers for Disease, C. and Prevention, *Vital signs: binge drinking among high school students and adults --- United States, 2009*. MMWR Morb Mortal Wkly Rep, 2010. **59**(39): p. 1274-9.
114. Renaud, S. and M. de Lorgeril, *Wine, alcohol, platelets, and the French paradox for coronary heart disease*. Lancet, 1992. **339**(8808): p. 1523-6.
115. Younossi, Z.M., et al., *Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C*. Aliment Pharmacol Ther, 2013. **37**(7): p. 703-9.
116. Shaper, A.G., G. Wannamethee, and M. Walker, *Alcohol and mortality in British men: explaining the U-shaped curve*. Lancet, 1988. **2**(8623): p. 1267-73.
117. Allaway, S.L., et al., *Detection of alcohol-induced fatty liver by computerized tomography*. J R Soc Med, 1988. **81**(3): p. 149-51.

118. Turner, R.T. and J.D. Sibonga, *Effects of alcohol use and estrogen on bone*. Alcohol Res Health, 2001. **25**(4): p. 276-81.
119. Santolaria, F., et al., *Nutritional assessment in alcoholic patients. Its relationship with alcoholic intake, feeding habits, organic complications and social problems*. Drug Alcohol Depend, 2000. **59**(3): p. 295-304.
120. Yin, J., et al., *Beverage-specific alcohol intake and bone loss in older men and women: a longitudinal study*. Eur J Clin Nutr, 2011. **65**(4): p. 526-32.
121. Iwaniec, U.T., T.J. Wronski, and R.T. Turner, *Histological analysis of bone*. Methods Mol Biol, 2008. **447**: p. 325-41.
122. Turner, R.T., et al., *Animal models for osteoporosis*. Rev Endocr Metab Disord, 2001. **2**(1): p. 117-27.
123. Grier, S.J., A.S. Turner, and M.R. Alvis, *The use of dual-energy x-ray absorptiometry in animals*. Invest Radiol, 1996. **31**(1): p. 50-62.
124. Gasser, J.A., *Bone measurements by peripheral quantitative computed tomography in rodents*. Methods Mol Med, 2003. **80**: p. 323-41.
125. Bouxsein, M.L., et al., *Guidelines for assessment of bone microstructure in rodents using micro-computed tomography*. J Bone Miner Res, 2010. **25**(7): p. 1468-86.
126. Baron, R., R. Tross, and A. Vignery, *Evidence of sequential remodeling in rat trabecular bone: morphology, dynamic histomorphometry, and changes during skeletal maturation*. Anat Rec, 1984. **208**(1): p. 137-45.
127. Erben, R.G., *Trabecular and endocortical bone surfaces in the rat: modeling or remodeling?* Anat Rec, 1996. **246**(1): p. 39-46.
128. Seeman, E., *Periosteal bone formation--a neglected determinant of bone strength*. N Engl J Med, 2003. **349**(4): p. 320-3.
129. Turner, R.T. and T.C. Spelsberg, *Correlation between mRNA levels for bone cell proteins and bone formation in long bones of maturing rats*. Am J Physiol, 1991. **261**(3 Pt 1): p. E348-53.
130. Martin, E.A., E.L. Ritman, and R.T. Turner, *Time course of epiphyseal growth plate fusion in rat tibiae*. Bone, 2003. **32**(3): p. 261-7.
131. Hillier, M.L. and L.S. Bell, *Differentiating human bone from animal bone: a review of histological methods*. J Forensic Sci, 2007. **52**(2): p. 249-63.
132. Lelovas, P.P., et al., *The laboratory rat as an animal model for osteoporosis research*. Comp Med, 2008. **58**(5): p. 424-30.
133. Lieber, C.S. and L.M. DeCarli, *Liquid diet technique of ethanol administration: 1989 update*. Alcohol Alcohol, 1989. **24**(3): p. 197-211.
134. Kidder, L.S. and R.T. Turner, *Dietary ethanol does not accelerate bone loss in ovariectomized rats*. Alcohol Clin Exp Res, 1998. **22**(9): p. 2159-64.
135. Sibonga, J.D., et al., *Effects of parathyroid hormone (1-34) on tibia in an adult rat model for chronic alcohol abuse*. Bone, 2007. **40**(4): p. 1013-20.
136. Brown, E.C., et al., *Skeletal toxicity associated with chronic ethanol exposure in a rat model using total enteral nutrition*. J Pharmacol Exp Ther, 2002. **301**(3): p. 1132-8.
137. Perrien, D.S., et al., *Interleukin-1 and tumor necrosis factor antagonists attenuate ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis*. J Pharmacol Exp Ther, 2002. **303**(3): p. 904-8.
138. Shankar, K., et al., *Chronic ethanol consumption inhibits postlactational anabolic bone rebuilding in female rats*. J Bone Miner Res, 2008. **23**(3): p. 338-49.

139. Maurel, D.B., et al., *Osteocyte apoptosis and lipid infiltration as mechanisms of alcohol-induced bone loss*. Alcohol Alcohol, 2012. **47**(4): p. 413-22.
140. Dyer, S.A., P. Buckendahl, and H.W. Sampson, *Alcohol consumption inhibits osteoblastic cell proliferation and activity in vivo*. Alcohol, 1998. **16**(4): p. 337-41.
141. Howe, K.S., U.T. Iwaniec, and R.T. Turner, *The effects of low dose parathyroid hormone on lumbar vertebrae in a rat model for chronic alcohol abuse*. Osteoporos Int, 2011. **22**(4): p. 1175-81.
142. Iwaniec, U.T., et al., *Effects of low-dose parathyroid hormone on bone mass, turnover, and ectopic osteoinduction in a rat model for chronic alcohol abuse*. Bone, 2008. **42**(4): p. 695-701.
143. Maurel, D.B., et al., *Combined effects of chronic alcohol consumption and physical activity on bone health: study in a rat model*. Eur J Appl Physiol, 2011. **111**(12): p. 2931-40.
144. Hogan, H.A., et al., *Adult-onset alcohol consumption induces osteopenia in female rats*. Alcohol Clin Exp Res, 2001. **25**(5): p. 746-54.
145. Nyquist, F., et al., *Ethanol and its effects on fracture healing and bone mass in male rats*. Acta Orthop Scand, 1999. **70**(2): p. 212-6.
146. Perrien, D.S., et al., *IL-1 and TNF antagonists prevent inhibition of fracture healing by ethanol in rats*. Toxicol Sci, 2004. **82**(2): p. 656-60.
147. Elmali, N., et al., *Fracture healing and bone mass in rats fed on liquid diet containing ethanol*. Alcohol Clin Exp Res, 2002. **26**(4): p. 509-13.
148. Trevisiol, C.H., et al., *Impaired osteoinduction in a rat model for chronic alcohol abuse*. Bone, 2007. **41**(2): p. 175-80.
149. Chakkalakal, D.A., et al., *Chronic ethanol consumption results in deficient bone repair in rats*. Alcohol Alcohol, 2002. **37**(1): p. 13-20.
150. Chakkalakal, D.A., et al., *Inhibition of bone repair in a rat model for chronic and excessive alcohol consumption*. Alcohol, 2005. **36**(3): p. 201-14.
151. Soares, E.V., et al., *Effects of alcohol and nicotine on the mechanical resistance of bone and bone neoformation around hydroxyapatite implants*. J Bone Miner Metab, 2010. **28**(1): p. 101-7.
152. Callaci, J.J., et al., *Binge alcohol treatment increases vertebral bone loss following ovariectomy: compensation by intermittent parathyroid hormone*. Alcohol Clin Exp Res, 2006. **30**(4): p. 665-72.
153. Callaci, J.J., et al., *Binge alcohol-induced bone damage is accompanied by differential expression of bone remodeling-related genes in rat vertebral bone*. Calcif Tissue Int, 2009. **84**(6): p. 474-84.
154. Lauing, K., et al., *Binge alcohol treatment of adolescent rats followed by alcohol abstinence is associated with site-specific differences in bone loss and incomplete recovery of bone mass and strength*. Alcohol, 2008. **42**(8): p. 649-56.
155. Wezeman, F.H., et al., *Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats*. Bone, 2007. **41**(4): p. 639-45.
156. Himes, R., F.H. Wezeman, and J.J. Callaci, *Identification of novel bone-specific molecular targets of binge alcohol and ibandronate by transcriptome analysis*. Alcohol Clin Exp Res, 2008. **32**(7): p. 1167-80.
157. Callaci, J.J., et al., *Long-term modulations in the vertebral transcriptome of adolescent-stage rats exposed to binge alcohol*. Alcohol Alcohol, 2010. **45**(4): p. 332-46.

158. Iwaniec, U.T. and R.T. Turner, *Intraperitoneal Injection of Ethanol Results in Drastic Changes in Bone Metabolism Not Observed when Ethanol Is Administered by Oral Gavage*. Alcohol Clin Exp Res, 2013.
159. Devlin, M.J., et al., *Caloric restriction leads to high marrow adiposity and low bone mass in growing mice*. J Bone Miner Res, 2010. **25**(9): p. 2078-88.
160. Hawkins, J., et al., *Energy restriction is associated with lower bone mineral density of the tibia and femur in lean but not obese female rats*. J Nutr, 2010. **140**(1): p. 31-7.
161. Grant, K.A. and A.J. Bennett, *Advances in nonhuman primate alcohol abuse and alcoholism research*. Pharmacol Ther, 2003. **100**(3): p. 235-55.
162. Chavassieux, P., et al., *In vitro evaluation of dose-effects of ethanol on human osteoblastic cells*. Bone Miner, 1993. **22**(2): p. 95-103.
163. Rosa, M.L., et al., *Chronic ethanol intake inhibits in vitro osteogenesis induced by osteoblasts differentiated from stem cells*. J Appl Toxicol, 2008. **28**(2): p. 205-11.
164. Friday, K.E. and G.A. Howard, *Ethanol inhibits human bone cell proliferation and function in vitro*. Metabolism, 1991. **40**(6): p. 562-5.
165. Klein, R.F., K.A. Fausti, and A.S. Carlos, *Ethanol inhibits human osteoblastic cell proliferation*. Alcohol Clin Exp Res, 1996. **20**(3): p. 572-8.
166. Klein, R.F. and A.S. Carlos, *Inhibition of osteoblastic cell proliferation and ornithine decarboxylase activity by ethanol*. Endocrinology, 1995. **136**(8): p. 3406-11.
167. Suh, K.T., et al., *Decreased osteogenic differentiation of mesenchymal stem cells in alcohol-induced osteonecrosis*. Clin Orthop Relat Res, 2005(431): p. 220-5.
168. Torricelli, P., et al., *Chronic alcohol abuse and endosseous implants: linkage of in vitro osteoblast dysfunction to titanium osseointegration rate*. Toxicology, 2008. **243**(1-2): p. 138-44.
169. Chen, J.R., et al., *Ethanol impairs estrogen receptor signaling resulting in accelerated activation of senescence pathways, whereas estradiol attenuates the effects of ethanol in osteoblasts*. J Bone Miner Res, 2009. **24**(2): p. 221-30.
170. Chen, J.R., et al., *Protective effects of estradiol on ethanol-induced bone loss involve inhibition of reactive oxygen species generation in osteoblasts and downstream activation of the extracellular signal-regulated kinase/signal transducer and activator of transcription 3/receptor activator of nuclear factor-kappaB ligand signaling cascade*. J Pharmacol Exp Ther, 2008. **324**(1): p. 50-9.
171. Cheung, R.C., et al., *Effects of ethanol on bone cells in vitro resulting in increased resorption*. Bone, 1995. **16**(1): p. 143-7.
172. Lorenz, R. and J. Janicke-Lorenz, *Electron microscopic observation on osteocytes of chronically alcoholized rats*. Arch Orthop Trauma Surg, 1983. **102**(2): p. 118-22.
173. Wang, Y., et al., *Alcohol-induced adipogenesis in bone and marrow: a possible mechanism for osteonecrosis*. Clin Orthop Relat Res, 2003(410): p. 213-24.
174. Vaananen, H.K., *Mesenchymal stem cells*. Ann Med, 2005. **37**(7): p. 469-79.
175. Beresford, J.N., et al., *Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures*. J Cell Sci, 1992. **102 ( Pt 2)**: p. 341-51.
176. Cui, Q., et al., *Alcohol-induced adipogenesis in a cloned bone-marrow stem cell*. J Bone Joint Surg Am, 2006. **88 Suppl 3**: p. 148-54.
177. Wezeman, F.H. and Z. Gong, *Adipogenic effect of alcohol on human bone marrow-derived mesenchymal stem cells*. Alcohol Clin Exp Res, 2004. **28**(7): p. 1091-101.

178. Giuliani, N., et al., *Ethanol and acetaldehyde inhibit the formation of early osteoblast progenitors in murine and human bone marrow cultures*. *Alcohol Clin Exp Res*, 1999. **23**(2): p. 381-5.
179. Hurley, M.M., et al., *Effects of ethanol and acetaldehyde on collagen synthesis, prostaglandin release and resorption of fetal rat bone in organ culture*. *Bone*, 1990. **11**(1): p. 47-51.
180. Chen, J.R., et al., *A role for ethanol-induced oxidative stress in controlling lineage commitment of mesenchymal stromal cells through inhibition of Wnt/beta-catenin signaling*. *J Bone Miner Res*, 2010. **25**(5): p. 1117-27.
181. Bonewald, L.F. and M.L. Johnson, *Osteocytes, mechanosensing and Wnt signaling*. *Bone*, 2008. **42**(4): p. 606-15.
182. Gruchow, H.W., et al., *Alcohol consumption, nutrient intake and relative body weight among US adults*. *Am J Clin Nutr*, 1985. **42**(2): p. 289-95.
183. Ivester, P., et al., *Ethanol self-administration and alterations in the livers of the cynomolgus monkey, *Macaca fascicularis**. *Alcohol Clin Exp Res*, 2007. **31**(1): p. 144-55.
184. Lindholm, J., et al., *Bone disorder in men with chronic alcoholism: a reversible disease?* *J Clin Endocrinol Metab*, 1991. **73**(1): p. 118-24.
185. Atkins, G.J., et al., *Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3*. *Bone*, 2007. **40**(6): p. 1517-28.
186. Khosla, S., et al., *Relationship between body composition and bone mass in women*. *J Bone Miner Res*, 1996. **11**(6): p. 857-63.
187. Nichols, D.L., et al., *Relationship of regional body composition to bone mineral density in college females*. *Med Sci Sports Exerc*, 1995. **27**(2): p. 178-82.
188. Robling, A.G. and C.H. Turner, *Mechanical signaling for bone modeling and remodeling*. *Crit Rev Eukaryot Gene Expr*, 2009. **19**(4): p. 319-38.
189. Ducy, P., et al., *Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass*. *Cell*, 2000. **100**(2): p. 197-207.
190. Thomas, T., et al., *Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes*. *Endocrinology*, 1999. **140**(4): p. 1630-8.
191. Otaka, M., et al., *Effect of alcohol consumption on leptin level in serum, adipose tissue, and gastric mucosa*. *Dig Dis Sci*, 2007. **52**(11): p. 3066-9.
192. Turner, R.T., C.J. Rosen, and U.T. Iwaniec, *Effects of alcohol on skeletal response to growth hormone in hypophysectomized rats*. *Bone*, 2010. **46**(3): p. 806-12.
193. Menagh, P.J., et al., *Growth hormone regulates the balance between bone formation and bone marrow adiposity*. *J Bone Miner Res*, 2010. **25**(4): p. 757-68.
194. Giustina, A., G. Mazziotti, and E. Canalis, *Growth hormone, insulin-like growth factors, and the skeleton*. *Endocr Rev*, 2008. **29**(5): p. 535-59.
195. Turner, R.T., et al., *Effects of ethanol on gene expression in rat bone: transient dose-dependent changes in mRNA levels for matrix proteins, skeletal growth factors, and cytokines are followed by reductions in bone formation*. *Alcohol Clin Exp Res*, 1998. **22**(7): p. 1591-9.
196. Lang, C.H., et al., *Modulation of the insulin-like growth factor system by chronic alcohol feeding*. *Alcohol Clin Exp Res*, 1998. **22**(4): p. 823-9.

197. Wezeman, F.H. and Z. Gong, *Bone marrow triglyceride accumulation and hormonal changes during long-term alcohol intake in male and female rats*. Alcohol Clin Exp Res, 2001. **25**(10): p. 1515-22.
198. Lavigne, J.A., et al., *Effects of alcohol on insulin-like growth factor I and insulin-like growth factor binding protein 3 in postmenopausal women*. Am J Clin Nutr, 2005. **81**(2): p. 503-7.
199. Amory, J.K., et al., *Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone*. J Clin Endocrinol Metab, 2004. **89**(2): p. 503-10.
200. Arisaka, O., et al., *Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism*. Metabolism, 1995. **44**(4): p. 419-23.
201. Dolan, S.E., S. Carpenter, and S. Grinspoon, *Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women*. J Acquir Immune Defic Syndr, 2007. **45**(2): p. 161-7.
202. Greendale, G.A., S. Edelstein, and E. Barrett-Connor, *Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study*. J Bone Miner Res, 1997. **12**(11): p. 1833-43.
203. Isaia, G., et al., *Effect of testosterone on bone in hypogonadal males*. Maturitas, 1992. **15**(1): p. 47-51.
204. Kenny, A.M., et al., *Determinants of bone density in healthy older men with low testosterone levels*. J Gerontol A Biol Sci Med Sci, 2000. **55**(9): p. M492-7.
205. Kenny, A.M., et al., *Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty*. J Am Geriatr Soc, 2010. **58**(6): p. 1134-43.
206. Pomerants, T., et al., *The influence of serum ghrelin, IGF axis and testosterone on bone mineral density in boys at different stages of sexual maturity*. J Bone Miner Metab, 2007. **25**(3): p. 193-7.
207. Slemenda, C.W., et al., *Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens*. J Clin Invest, 1997. **100**(7): p. 1755-9.
208. Stepan, J.J., et al., *Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling*. J Clin Endocrinol Metab, 1989. **69**(3): p. 523-7.
209. Snyder, P.J., et al., *Effect of testosterone treatment on bone mineral density in men over 65 years of age*. J Clin Endocrinol Metab, 1999. **84**(6): p. 1966-72.
210. Verhas, M., et al., *The effect of orchidectomy on bone metabolism in aging rats*. Calcif Tissue Int, 1986. **39**(2): p. 74-7.
211. Turner, R.T., G.K. Wakley, and K.S. Hannon, *Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats*. J Orthop Res, 1990. **8**(4): p. 612-7.
212. Wakley, G.K., et al., *Androgen treatment prevents loss of cancellous bone in the orchidectomized rat*. J Bone Miner Res, 1991. **6**(4): p. 325-30.
213. Vanderschueren, D., et al., *Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency*. Endocrinology, 1992. **130**(5): p. 2906-16.
214. Ke, H.Z., et al., *Long-term effects of aging and orchidectomy on bone and body composition in rapidly growing male rats*. J Musculoskelet Neuronal Interact, 2001. **1**(3): p. 215-24.



215. Onland-Moret, N.C., et al., *Alcohol and endogenous sex steroid levels in postmenopausal women: a cross-sectional study*. J Clin Endocrinol Metab, 2005. **90**(3): p. 1414-9.
216. Maneesh, M., et al., *Alcohol abuse-duration dependent decrease in plasma testosterone and antioxidants in males*. Indian J Physiol Pharmacol, 2006. **50**(3): p. 291-6.
217. Mendelson, J.H., N.K. Mello, and J. Ellingboe, *Effects of acute alcohol intake on pituitary-gonadal hormones in normal human males*. J Pharmacol Exp Ther, 1977. **202**(3): p. 676-82.
218. Persky, H., et al., *The effect of alcohol and smoking on testosterone function and aggression in chronic alcoholics*. Am J Psychiatry, 1977. **134**(6): p. 621-5.
219. Sierksma, A., et al., *Effect of moderate alcohol consumption on plasma dehydroepiandrosterone sulfate, testosterone, and estradiol levels in middle-aged men and postmenopausal women: a diet-controlled intervention study*. Alcohol Clin Exp Res, 2004. **28**(5): p. 780-5.
220. Mello, N.K., et al., *Alcohol effects on luteinizing hormone and testosterone in male macaque monkeys*. J Pharmacol Exp Ther, 1985. **233**(3): p. 588-96.
221. Badr, F.M. and A. Bartke, *Effect of ethyl alcohol on plasma testosterone level in mice*. Steroids, 1974. **23**(6): p. 921-8.
222. Badr, F.M., et al., *Suppression of testosterone production by ethyl alcohol. Possible mode of action*. Steroids, 1977. **30**(5): p. 647-55.
223. Rivier, C., *Alcohol rapidly lowers plasma testosterone levels in the rat: evidence that a neural brain-gonadal pathway may be important for decreased testicular responsiveness to gonadotropin*. Alcohol Clin Exp Res, 1999. **23**(1): p. 38-45.
224. Cigolini, M., et al., *Moderate alcohol consumption and its relation to visceral fat and plasma androgens in healthy women*. Int J Obes Relat Metab Disord, 1996. **20**(3): p. 206-12.
225. Turner, R.T., B.L. Riggs, and T.C. Spelsberg, *Skeletal effects of estrogen*. Endocr Rev, 1994. **15**(3): p. 275-300.
226. Felson, D.T., et al., *The effect of postmenopausal estrogen therapy on bone density in elderly women*. N Engl J Med, 1993. **329**(16): p. 1141-6.
227. Cauley, J.A., et al., *Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group*. Ann Intern Med, 1995. **122**(1): p. 9-16.
228. Colantoni, A., et al., *Hepatic estrogen receptors and alcohol intake*. Mol Cell Endocrinol, 2002. **193**(1-2): p. 101-4.
229. Singletary, K.W., R.S. Frey, and W. Yan, *Effect of ethanol on proliferation and estrogen receptor-alpha expression in human breast cancer cells*. Cancer Lett, 2001. **165**(2): p. 131-7.
230. Chung, K.W., *Effects of chronic ethanol intake on aromatization of androgens and concentration of estrogen and androgen receptors in rat liver*. Toxicology, 1990. **62**(3): p. 285-95.
231. Gordon, G.G., et al., *The effect of alcohol ingestion on hepatic aromatase activity and plasma steroid hormones in the rat*. Metabolism, 1979. **28**(1): p. 20-4.
232. Ginsburg, E.S., et al., *The effect of acute ethanol ingestion on estrogen levels in postmenopausal women using transdermal estradiol*. J Soc Gynecol Investig, 1995. **2**(1): p. 26-9.

233. Hoffman, A.R., et al., *Ethanol reduces hepatic estrogen-2-hydroxylase activity in the male rat*. Life Sci, 1981. **29**(8): p. 789-94.
234. Gavaler, J.S. and D.H. Van Thiel, *The association between moderate alcoholic beverage consumption and serum estradiol and testosterone levels in normal postmenopausal women: relationship to the literature*. Alcohol Clin Exp Res, 1992. **16**(1): p. 87-92.
235. Gavaler, J.S., *Should we consider an acceptable drinking level specifically for postmenopausal women? Preliminary findings from the postmenopausal health disparities study*. Alcohol Alcohol, 2005. **40**(5): p. 469-73.
236. Nagata, C., et al., *Associations of alcohol, height, and reproductive factors with serum hormone concentrations in postmenopausal Japanese women. Steroid hormones in Japanese postmenopausal women*. Breast Cancer Res Treat, 1997. **44**(3): p. 235-41.
237. Reichman, M.E., et al., *Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women*. J Natl Cancer Inst, 1993. **85**(9): p. 722-7.
238. Rinaldi, S., et al., *Relationship of alcohol intake and sex steroid concentrations in blood in pre- and post-menopausal women: the European Prospective Investigation into Cancer and Nutrition*. Cancer Causes Control, 2006. **17**(8): p. 1033-43.
239. Dorgan, J.F., et al., *The relation of reported alcohol ingestion to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States)*. Cancer Causes Control, 1994. **5**(1): p. 53-60.
240. Mendelson, J.H., et al., *Acute alcohol effects on plasma estradiol levels in women*. Psychopharmacology (Berl), 1988. **94**(4): p. 464-7.
241. Mendelson, J.H., et al., *Alcohol effects on luteinizing hormone releasing hormone-stimulated anterior pituitary and gonadal hormones in women*. J Pharmacol Exp Ther, 1989. **250**(3): p. 902-9.
242. Grant, K.A., et al., *Characterization of the discriminative stimulus effects of GABA(A) receptor ligands in Macaca fascicularis monkeys under different ethanol training conditions*. Psychopharmacology (Berl), 2000. **152**(2): p. 181-8.
243. Floyd, D.W., et al., *Long-term ethanol self-administration by cynomolgus macaques alters the pharmacology and expression of GABAA receptors in basolateral amygdala*. J Pharmacol Exp Ther, 2004. **311**(3): p. 1071-9.
244. Anderson, N.J., et al., *Long-term ethanol self-administration by the nonhuman primate, Macaca fascicularis, decreases the benzodiazepine sensitivity of amygdala GABA(A) receptors*. Alcohol Clin Exp Res, 2007. **31**(6): p. 1061-70.
245. Hemby, S.E., et al., *Ethanol-induced regulation of GABA-A subunit mRNAs in prefrontal fields of cynomolgus monkeys*. Alcohol Clin Exp Res, 2006. **30**(12): p. 1978-85.
246. Acosta, G., et al., *Ethanol self-administration modulation of NMDA receptor subunit and related synaptic protein mRNA expression in prefrontal cortical fields in cynomolgus monkeys*. Brain Res, 2010. **1318**: p. 144-54.
247. Ariwodola, O.J., et al., *Ethanol modulation of excitatory and inhibitory synaptic transmission in rat and monkey dentate granule neurons*. Alcohol Clin Exp Res, 2003. **27**(10): p. 1632-9.
248. Burnett, E.J., et al., *The effects of chronic ethanol self-administration on hippocampal serotonin transporter density in monkeys*. Front Psychiatry, 2012. **3**: p. 38.
249. Elefteriou, F., *Neuronal signaling and the regulation of bone remodeling*. Cell Mol Life Sci, 2005. **62**(19-20): p. 2339-49.

250. Helms, C.M., et al., *A longitudinal analysis of circulating stress-related proteins and chronic ethanol self-administration in cynomolgus macaques*. *Alcohol Clin Exp Res*, 2012. **36**(6): p. 995-1003.
251. Helms, C.M., et al., *Diurnal pituitary-adrenal activity during schedule-induced polydipsia of water and ethanol in cynomolgus monkeys (Macaca fascicularis)*. *Psychopharmacology (Berl)*, 2013.
252. Isales, C.M., M. Zaidi, and H.C. Blair, *ACTH is a novel regulator of bone mass*. *Ann N Y Acad Sci*, 2010. **1192**: p. 110-6.
253. Iotsova, V., et al., *Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2*. *Nat Med*, 1997. **3**(11): p. 1285-9.
254. Bellido, T., et al., *Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation*. *Endocrinology*, 1997. **138**(9): p. 3666-76.
255. Grant, K.A., et al., *Drinking typography established by scheduled induction predicts chronic heavy drinking in a monkey model of ethanol self-administration*. *Alcohol Clin Exp Res*, 2008. **32**(10): p. 1824-38.
256. Muller, R., et al., *Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography*. *Bone*, 1998. **23**(1): p. 59-66.
257. Odgaard, A. and H.J. Gundersen, *Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions*. *Bone*, 1993. **14**(2): p. 173-82.
258. Hildebrand, T. and P. Ruegsegger, *Quantification of Bone Microarchitecture with the Structure Model Index*. *Comput Methods Biomech Biomed Engin*, 1997. **1**(1): p. 15-23.
259. Haaber, A.B., et al., *Bone mineral metabolism, bone mineral density, and body composition in patients with chronic pancreatitis and pancreatic exocrine insufficiency*. *Int J Pancreatol*, 2000. **27**(1): p. 21-7.
260. Maurel, D.B., et al., *Alcohol and bone: review of dose effects and mechanisms*. *Osteoporos Int*, 2012. **23**(1): p. 1-16.
261. Majchrowicz, E. and J.H. Mendelson, *Blood concentrations of acetaldehyde and ethanol in chronic alcoholics*. *Science*, 1970. **168**(3935): p. 1100-2.
262. Mello, N.K. and J.H. Mendelson, *Experimentally induced intoxication in alcoholics: a comparison between programmed and spontaneous drinking*. *J Pharmacol Exp Ther*, 1970. **173**(1): p. 101-16.
263. Mello, N.K. and J.H. Mendelson, *A quantitative analysis of drinking patterns in alcoholics*. *Arch Gen Psychiatry*, 1971. **25**(6): p. 527-39.